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Aberrant alternative splicing of hereditary breast and ovarian cancer genes has been associated with 
an increased susceptibility for breast and/or ovarian cancer. However, studying the effects of gene 
variants on splicing patterns proves to be difficult for classifying Variants of Uncertain Significance 
(VUS) – variants which lack the evidence to be categorised as benign or pathogenic. This is 
particularly the case for the BRCA1 gene, which is poorly expressed, with a long transcript length.  
 
In this study, a novel RNA enrichment technique using the Oxford Nanopore MinION long-read 
sequencer was developed and tested to alleviate these limitations. The main hypotheses were that 
direct RNA sequencing can identify full-length splice isoforms of genes of interest, and that these 
results can be enhanced using a novel gene enrichment technique. 
 
Total RNA was extracted from a control lymphoblastoid cell line and reverse-transcribed into cDNA. 
Second-strand cDNA synthesis was carried out by incorporating a T7-polymerase binding site 
attached to a gene-specific primer for the genes of interest. In vitro transcription was carried out with 
T7-polymerase to enrich the RNA isoforms, which were then sequenced with the Direct RNA 
Sequencing Kit (Oxford Nanopore Technologies, UK). Several bioinformatic pipelines were 
evaluated, as bespoke pipelines for analysing this novel dataset were unavailable. The final pipeline 
consisted of alignment to the Human Genome Reference Build 38 with Minimap2, conversion to 
BAM files, sorting and indexing with Samtools. The output file was visualised on the Integrative 
Genomics Viewer, and the reads were manually counted and processed in Excel.  
 
The results exhibited evidence of transcript enrichment for three genes of interest (BRCA1, RAD51C, 
CHEK2) and a control gene (GAPDH). Of note, GAPDH presented isoform abundance ratios which 
were similar in three separate experiments, indicating potentially quantitative and reproducible linear 
enrichment. Full-length isoforms of GAPDH, RAD51C and BRCA1 were able to be sequenced with 
the Direct RNA Sequencing Kit. Additionally, novel isoforms which have not been previously 
described for RAD51C were detected, which include Δ 3,5-6, Δ 3,7 and Δ 4,7 
 
Novel methodologies and proof-of-principle experiments were executed to enrich and analyse 
specific transcripts using direct RNA nanopore sequencing. The enrichment method should be further 
validated with other approaches such as RT-qPCR and optimised for use with relevant genes. 
Provided that a bespoke pipeline for long direct RNA sequencing becomes available, this novel 
method may provide a powerful new approach for interpreting the clinical significance of variants of 
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Chapter 1: Introduction 
 
1.1 Overview 
Breast cancer is a prevalent disease among the global population, thus, it is of importance to 
study the mechanisms behind this disease. Studies within the past two decades have identified 
that the onset of this disease is linked to pathogenic variants of hereditary breast and ovarian 
cancer genes, which include BRCA1. While genetic screening tests can detect gene variants in 
such genes, determining the significance of these variants proves to be difficult (Duzkale et al., 
2013). A group of variants named Variants of Uncertain Significance (VUS) have an uncertain 
clinical significance and can cause complications for clinical action. Alternative splicing of pre-
mRNA has been linked to the onset of breast cancer (Menon & Omenn, 2010; Stickeler, Kittrell, 
Medina, & Berget, 1999), and provides important evidence for classifying gene variants. 
However, determining which mRNA splice changes are abnormal and potentially deleterious can 
be challenging.  
One main challenge can be attributed to RNA sequencing limitations. For instance, studying 
large genes such as BRCA1 reveals difficulties with short-read sequencers such as Sanger or 
Illumina. Fortunately, the advent of nanopore sequencing technology developed by Oxford 
Nanopore Technologies (ONT) has mitigated the limitations of standard sequencers and may 
prove to be a better alternative. Nanopore sequencing has prospects of delivering affordable and 
accessible long-read Direct RNA Sequencing (DRS); the direct sequencing of RNA molecules. 
The second challenge can be associated with the low expression levels of the genes of interest, 
leading to an increased difficulty in analysing different isoforms. The purpose of this project was 
to use the MinION nanopore sequencer to develop a novel method to explore the potential of 
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long-read DRS for understanding effects of VUS on RNA splicing. Thus, the use of this method 
to identify the effect of rare VUS impacting on RNA splicing may be valuable and ground-
breaking in the fields of oncology and genetics.  
 
1.2 Breast cancer statistics 
In the 2018 report by the International Agency for Research on Cancer, female breast cancer was 
determined as the second most prevalent cause of cancer death worldwide, comprising 11.6 % of 
all cancer mortalities across 185 countries. Furthermore, it is estimated that approximately 2.1 
million new cases of female breast cancer will arise in 2018 (F. Bray et al., 2018). In contrast, 
male breast cancer has found to only comprise around 0.5-1 % of total breast cancer cases 
(Yalaza, Inan, & Bozer, 2016). Similar trends have been observed in the New Zealand Ministry 
of Health dataset in 2015, where breast cancer was a part of the ten most prevalent cancers in the 
new cancer registration (New Zealand Ministry of Health, 2017). Age-standardised registration 
rates show that breast cancer constitutes approximately 51.6 registrations per 100,000 of the total 
population. Males contributed to 0.7 registrations per 100,000 of the male population and 
females contributed to 98.4 registrations per 100,000 of the female population, which shows that 
female registrations dominate over male registrations in New Zealand. Registration rates of the 
Maori and non-Maori population were 70.5 registrations per 100,000, and 49.5 registrations per 
100,000 respectively, which shows that a greater proportion of breast cancer patients are of 
Maori descent in New Zealand (New Zealand Ministry of Health, 2017). Although absolute 
numbers of New Zealand breast cancer cases are low, New Zealand female breast cancer rates 




1.3. Hereditary breast and ovarian cancer genes 
Hereditary breast cancer accounts for 5-10 % of all cases of breast cancer (F. Bray et al., 2018) and 
the associated genes include ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, FANCM, NBN, 
PALB2, RAD51B, RAD51C and RAD51D. The list of full names of these genes are outlined 
below (Table 1.1). These genes have a wide range of different functions, transcript lengths and 
expression levels. Furthermore, pathogenic variants of hereditary breast and ovarian cancer 
genes increase the risk of developing breast and/or ovarian cancers. 
 
 
Table 1. 1 List of hereditary breast and ovarian cancer genes with common and full names 
Common gene name Full gene name 
ATM Ataxia Telangiectasia Mutated gene 
BARD1 BRCA1-Associated Ring Domain Protein 1 gene 
BRCA1 Breast Cancer Type 1 Susceptibility Protein gene 
BRCA2 Breast Cancer Type 2 Susceptibility Protein gene 
BRIP1 BRCA1 Interacting Helicase 1 gene 
CHEK2 Checkpoint Kinase 2 gene 
FANCM Fanconi Anaemia Complementation Group M gene 
NBN Nibrin gene 
PALB2 Partner and Localiser of BRCA2 gene 
RAD51B RAD51 Paralog B gene 
RAD51C RAD51 Paralog C gene 





Certain variants of hereditary breast and ovarian cancer genes have been found to affect the 
function of the resulting protein by disrupting mechanisms such as transcription (Nadeau et al., 
2000) and translation (Dacheux et al., 2013). One example of a post-translational modification 
affected by gene variants is phosphorylation (Tram, Savas, & Ozcelik, 2013). Phosphorylation is 
the attachment of a phosphoryl group, which regulates the function of many enzymes (Burnett & 
Kennedy, 1954). It is important for gene function, where missense mutations may cause 
disruptions by altering kinase recognition and phosphorylation patterns of the cell cycle. 
BRCA1 was identified in Marie Claire-King's laboratory in 1990 and it is amongst the most 
widely studied of these genes (Hall et al., 1990). The BRCA1 gene is located on chromosome 
arm 17q at region 2 band 1 (Hall et al., 1990; Narod et al., 1991) and contains a Zinc Finger 
CH3C4 Type (RING Finger) domain (Miki et al., 1994) and a BRCA1 C Terminus (BRCT) 
domain (Bork et al., 1997; Koonin, Altschul, & Bork, 1996) (Figure 1.1). Functions of BRCA1 
are well studied, which include being involved in DNA repair (Scully et al., 1997), checkpoint 
control (Yu & Chen, 2004), ubiquitination (Morris & Solomon, 2004), chromatin remodelling 









The protein is composed of 1853 amino acids. BARD1 binds to the RING finger domain, BRCA2, 
BACH1, CtIP, RNAP II bind to the BRCT repeats and the MRN complex binds to the Nuclear 
Localisation Signals (NLS). Reproduced with permission (West, 2003). 
 
 
In 1994, BRCA2, which functions in DNA repair of double-strand breaks by homologous 
recombination (Patel et al., 1998; F. Xia et al., 2001), was localised to 13q12-q13 (Wooster et al., 
1994). The BRCA2 protein interacts closely with the RAD51 protein (Sharan et al., 1997). 
RAD51 is a well-conserved gene, with a protein which functions in homologous recombination 
and double-stranded break repair (Shinohara, Ogawa, & Ogawa, 1992). The gene has paralogs 
such as RAD51B (Albala et al., 1997), RAD51C (Dosanjh et al., 1998) and RAD51D (Pittman, 
Weinberg, & Schimenti, 1998), which are hereditary breast and ovarian cancer genes. ATM 
encodes for a Serine/Threonine kinase, which is activated by DNA damage including double-
stranded breaks (Shiloh, 2006). This gene was found to be important for regulating the 
 
Figure 1. 1 The structure of the BRCA1 protein and its interactions. 
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phosphorylation of BRCA1 (Cortez, Wang, Qin, & Elledge, 1999) and regulation of CHEK2 
(Matsuoka, Huang, & Elledge, 1998). CHEK2 encodes for the protein Checkpoint Kinase 2 
(CHK2), which is phosphorylated in response to DNA damage, in an ATM-dependent manner 
(Matsuoka et al., 1998). It is known to phosphorylate Serine 988 of BRCA1 after DNA damage, 
which allows the dispersal of the BRCA1 protein (Zhang et al., 2004). Furthermore, it is 
important in restoring survival (J. S. Lee, Collins, Brown, Lee, & Chung, 2000) and is involved 
in cell cycle regulation at the G2 phase. FANCM is one of the Fanconi Anemia (FA) genes, 
known to repair the inter-strand cross-linking regions by acting as a helicase or translocase and 
recruits the core FA complex (Meetei et al., 2005). BARD1 protein relocates BRCA1 to DNA 
damage sites through tandem BRCT modules, which may allow repair of DNA regions in cells 
which have lost phosphorylation-dependent pathways (M. Li & Yu, 2013). 
BRIP1/BACH1/FANCJ encodes for a DNA-dependent ATPase and a 5’ to 3’ helicase (S. Cantor 
et al., 2004), necessary for the normal functioning of the double-strand break repair mechanism 
of BRCA1 by interacting with the BRCT domain (S. B. Cantor et al., 2001). PALB2 interacts 
with and promotes the localisation of BRCA2 by co-localisation and allows the repair and 
checkpoint regulation (B. Xia et al., 2006). The protein products of the NBN gene are named 
p53/Nibrin/NBS1, and form a part of the MRN complex along with MRE11 and RAD50, which 







1.4 Carrier testing 
High-risk individuals with a family history of breast and/or ovarian cancer may be referred for a 
genetic screening test to determine their predisposition to hereditary cancer. Many variations of 
genetic screening services are available for high-risk individuals, whereby the type of laboratory 
test utilised is dependent on each clinic. Initial clinical genetic screening for mutations 
within BRCA1 were monopolised by Myriad Genetics, which made these tests unaffordable and 
inaccessible to many high-risk family members. However, a court ruling in 2010 revoked the 
patent, which allowed other companies to competitively decrease the prices of these genetic 
screening tests (Kesselheim & Mello, 2010).  
 
Carrier testing for hereditary breast and ovarian cancer genes by multiplex gene panels, include, 
but are not restricted to BRCA1 and BRCA2 (Beaudet, 2015; Crawford et al., 2017; Grindedal et 
al., 2017; Howarth et al., 2015). These panels range from small panels with high penetrance 
genes, to larger panels with a broader scope of genes (Shiovitz & Korde, 2015). Next-generation 
sequencing - a relatively rapid, massively parallel sequencing method (Behjati & Tarpey, 2013) - 
was the most favoured variant detection method in non-American laboratories, whereas next 
generation and Sanger sequencing were equally favoured in American laboratories. Furthermore, 
Multiplex Ligation-dependent Probe Amplification - a multiplex PCR assay (Schouten et al., 
2002) - was the most favoured approach for deletion/duplication detection in non-American 
laboratories (Toland et al., 2018). 
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1.5 The Variants of Uncertain Significance (VUS) problem 
Common obstacles to screening processes are VUS; genetic variants with an unclarified clinical 
significance (Millot et al., 2012). The approximate proportion of VUS of BRCA1/2 genetic 
testing outcomes are 5-10 % (Lattimore et al., 2015), and rare VUS which impact on alternative 
splicing are difficult to identify without patient tissue. Individuals carrying a VUS in a 
susceptibility gene are unlikely to receive prophylactic treatment based on the genetic test alone, 
as these risk-reducing measures may involve invasive surgical procedures (Eggington et al., 
2014). However, family and medical history are implemented to allow prevention schemes to be 
applied to these individuals (Weitzel et al., 2003). The outcome of a VUS was reported to 
generate higher psychological stress (O'Neill et al., 2009), although this concept is conflicting 
with other studies (S. van Dijk et al., 2004). Overall, constructing more evidence for classifying 
these VUS is paramount. Unfortunately, while many international collaborations are taking place 
to further classify these VUS, more novel VUS are being continually identified (Duzkale et al., 
2013). Evidence shows that in 2012, over 500 missense VUS were noted for BRCA1 alone, and 
this number is hypothesised to increase over the years (Millot et al., 2012; National Human 
Genome Research Institute). Furthermore, approximately 100 New Zealanders in the past decade 
have been notified with the discovery of VUS during a screening test (Lattimore et al., 2015). 
Regardless of these findings, genetic screening should be offered on a wider scale, as the benefits 
of detecting pathogenic variants outweigh the expanding problem of VUS amassment (Duzkale 
et al., 2013; Grindedal et al., 2017). However, a contrasting position is taken by another study 
which showed that in fact, the VUS rate declined from 12.8 % to 2.1 % of all results (Eggington 
et al., 2014). These results may be attributed to the increased usage of tests and the advent of 
improved screening methods (Lattimore et al., 2015).  
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1.6 Classifying variants of uncertain significance  
According to existing surveys, detecting rare VUS which impact on alternative splicing and 
providing evidence to classify these VUS, are laborious processes (Cheon, Mozersky, & Cook-
Deegan, 2014) (Figure 1.2). A few approaches have been proposed for classifying VUS. These 
include using in silico approaches such as multifactorial probability-based models (Lindor et al., 
2012), and biological approaches such as RNA transcript analysis (Thomassen et al., 2012) and 
embryonic stem cell-based functional assays (Chang, Biswas, Martin, Stauffer, & Sharan, 2009). 
Broader methods may include finding the same variants in family members (Cheon et al., 2014) 
and using animal models (Hakem et al., 1996). Furthermore, increasing the accuracy of current 
approaches has been beneficial for classification.  
 
In particular, RNA transcript analysis has been indicated by the Evidence-based Network for the 
Interpretation of Germline-Mutant Alleles (ENIGMA) consortium to be a substantial method of 
providing evidence for classifying a subset of VUS. The consortium has provided evidence that 
capillary electrophoresis, Polymerase Chain Reaction (PCR) and sequencing are valid semi-
quantitative methods for transcript splicing analysis (Colombo et al., 2014; Whiley et al., 2014). 
Historically, PCR methods have been used to analyse aberrant splicing by evaluating variants 
located near or within intron-exon boundaries (Chen et al., 2006; de Jong et al., 2017). Further 
studies have utilised mini-gene splicing assays for characterising the impact of splicing 
alterations (Ahlborn et al., 2015). Quantitative PCR methods have also been utilised as a 
quantitative method of analysing splice isoforms for VUS classification (Vandenbroucke, 
Vandesompele, Paepe, & Messiaen, 2001; Walker et al., 2010). However, they are unable to 
provide qualitative information about specific transcript sequences. Recently, CloneSeq, a novel 
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high-throughput massively parallel RNA sequencing assay which is able to provide qualitative 
and quantitative data, was developed (Farber-Katz et al., 2018). Overall, all approaches of 
visualising alternative splicing effects utilise cDNA as the molecule of interest instead of RNA, 
which may be a considerable limitation for these approaches.  
 
The abovementioned methods may aid in classification of VUS, however, the scope of 
classification levels is variable between different clinics.  For instance, one study uses a 5-tier 
system composed of 'deleterious', 'suspected deleterious', 'VUS', 'genetic variant favour 
polymorphism' and 'polymorphism' levels (Eggington et al., 2014). In contrast, another 
implemented a 4-tier categorisation method composed of 'non-mutation', 'pathogenic variant', 
'polymorphism/neutral variant' and 'VUS' levels (Millot et al., 2012). The wide variety of 






A laboratory result reveals the variant carried by the tested individual. The variant is annotated with 
external data, and classified into 5 categories; benign, likely benign, VUS, likely pathogenic, and 








Figure 1. 2 Classification workflow of variant classification. 
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1.7 Splicing  
A subset of VUS which impact on splicing may be classified by visualising the effect of gene 
variants on alternative splicing patterns with RNA transcript analyses. Splicing is the process 
whereby a section of a pre-mRNA transcript is removed, and the remaining sequences are joined 
together (Figure 1.3). This principle explains the non-uniformity between the number of human 
genes and proteins, which is a widely accepted concept. Hence, the concept of 'one gene–one 
RNA-one protein' is no longer recognised, as splicing has been found to affect 95% of human 
multi-exon genes (Pan, Shai, Lee, Frey, & Blencowe, 2008). 
 
The 5’ and 3’ exons are spliced together by intron removal through the formation of a lariat structure. 
Reproduced with permission (Baralle & Baralle, 2005). 
Figure 1. 3 A brief schematic of a splicing event. 
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Two forms of splicing exist; constitutive and alternative splicing. Constitutive splicing is the 
exon-joining and intron-removal in the order of most genes, whereas alternative splicing 
facilitates exon-skipping to produce different mature mRNA isoforms (Maki et al., 1981). The 
interplay between alternative transcription start sites, transcription end sites, alternative splice 
sites, exon-skipping and intron-retention all contribute to the final form of the mRNA transcript.  
Splicing is regulated by trans-acting factors and cis-acting elements, and their mechanisms are 
well documented in the literature (Berget, Moore, & Sharp, 1977; Breitbart & Nadal-Ginard, 
1987; Delsert, Morin, & Klessig, 1989; Fu & Manley, 1987). The cis-acting elements include 
Intronic Splicing Enhancers (ISE), Intronic Splicing Silencers (ISS), Exonic Splicing Enhancers 
(ESE) and Exonic Splicing Silencers (ESS). The enhancers are bound by positive trans-acting 
factors, such as the Serine/Arginine-rich family of nuclear phosphoproteins (SR proteins) (Ge & 
Manley, 1990) (Figure 1.4), and the silencers are bound by negative trans-acting factors such as 
heterogeneous nuclear ribonucleoproteins (hnRNPs). The splicing itself is carried out by a 
protein-RNA complex called the spliceosome by targeting the 5' and 3' regions. The spliceosome 
is formed by more than 170 proteins and 5 small nuclear RNAs (snRNAs) (Behzadnia et al., 
2007). The recognition of the 5' GU and the 3' AG of introns leads to the out-splicing of certain 
introns to form the mature mRNA. This mechanism commences with the U1 small nuclear 
riboprotein (snRNP) binding to the 5' splice site (Siliciano & Guthrie, 1988), and the Splicing 
Factor 1 (SF1) binding to the branch point (Berglund, Chua, Abovich, Reed, & Rosbash, 1997). 
This leads to the U2 snRNP auxiliary factor (U2AF) binding to the 3' splice site to facilitate the 
binding of U2 to the branch point (Ruskin, Zamore, & Green, 1988). The commitment to 
splicing occurs through the substitution of SF1 by U2 snRNP, which forms the pre-spliceosomal 
A complex (Kramer & Utans, 1991). The A complex converts to the B (Wolf et al., 2009) and C 
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(Zhan, Yan, Zhang, Lei, & Shi, 2018) complexes which facilitates the removal of the intron and 




Factors bind to regulatory regions in order to ensure that the exon which is to be spliced by the 
spliceosome can be recognised. The figure represents two SR-proteins binding to an Exonic Splicing 






Figure 1. 4 Brief schematic of spliceosomal action during splicing. 
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1.8 Alternative splicing 
Alternative splicing appears to have a profound effect in contributing to proteome diversity 
(Gueroussov et al., 2015) and isoform function by affecting most cellular processes. Firstly, 
isoforms are involved in changing global cellular mechanisms. An example is the process of 
apoptosis, whereby alternative splicing acts as a switch for pro-apoptotic or anti-apoptotic 
enzymes (Vegran, Boidot, Solary, & Lizard-Nacol, 2011). This mechanism may be cell-type 
dependent (Caldas, Fangusaro, Boue, Holloway, & Altura, 2007). Alternative splicing also 
affects transcription factors by affecting the protein-complex forming system. For instance, the 
skipping of an exon with DNA binding ability will produce transcription factors which have lost 
the ability to bind to promoters. Moreover, the regulation of such mechanisms is also affected by 
alternative splicing (Goodson, Jonas, & Privalsky, 2005). Additionally, the localisation of 
proteins is affected by splicing. Certain variants of the enzyme Drosha were localised to the 
cytoplasm while two others were localised to the nucleus (Link, Grund, & Diederichs, 2016). 
Additionally, the Divalent Metal Transporter 1 (DMT1) exhibits clear intracellular localisation 
patterns which are isoform-dependent (Tabuchi, Tanaka, Nishida-Kitayama, Ohno, & Kishi, 
2002), which further supports this concept. Furthermore, the splicing mechanism can inactivate 
and modulate enzymes in a variety of ways. For example, the cytosolic phospholipase A2 beta 
changes the substrate specificity due to alternative splicing (Ghosh, Tucker, Burchett, & Leslie, 
2006). Other functions of alternatively spliced isoforms include involvement in forming protein 
domains (Kelemen et al., 2013), channel proteins (Vallejo-Illarramendi, Domercq, & Matute, 
2005) and binding properties between proteins (Belfiore, Frasca, Pandini, Sciacca, & Vigneri, 
2009). Moreover, an interesting study suggests that certain isoforms may only be functional as a 
result of other related isoforms being expressed by a change in splicing (Kelemen et al., 2013).  
16 
 
Aberrant alternative splicing is known to be strongly associated with diseases, which is expected 
given the involvement of alternative splicing in protein function and regulation. The relevance to 
cancer diagnosis, management and therapeutics is important to acknowledge, as numerous 
studies have shown that aberrant alternative splicing contributes to cancer formation (S. Li, Hu, 
Zhao, Huang, & He, 2018; Z. Li et al., 2015; Miyamoto et al., 2018). An example of a well-
noted alternative splicing isoform of BRCA1 is the Δ11/11q isoform, which involves skipping of 
the whole or part of the largest exon in the BRCA1 gene, respectively (Tammaro, Raponi, 
Wilson, & Baralle, 2014). Exon 11 contains regulatory sequences which are important in 
alternative splicing regulation (Raponi, Douglas, Tammaro, Wilson, & Baralle, 2012) and the 
skipping of this exon is believed to promote growth and survival of tumour cells (Tammaro, 
Raponi, Wilson, & Baralle, 2012). Thus, new therapeutic approaches may be found by 
recognising the relevance of these aberrant alternative splice isoforms (S. C. Lee & Abdel-
Wahab, 2016). This may be achieved using multiple bioinformatic prediction programmes 
(Spurdle et al., 2008).  
 
Nonsense-Mediated Decay (NMD) is a method of splicing regulation by degradation of mRNA 
isoforms with premature stop codons 50 bps upstream of the exon junction complex (Nagy & 
Maquat, 1998). However, other functions of NMD have been found, which include regulation of 
physiological transcript expression (Mendell, Sharifi, Meyers, Martinez-Murillo, & Dietz, 2004). 
NMD inhibitors such as cycloheximide allow retention and visualisation of transcripts that would 




Additionally, while exon-skipping is the most common type of alternative splicing in humans, 
other types of alternative splicing such as NAGNAG splicing exist. This involves tandem 
acceptors separated by three nucleotides and results in two splice variants; the E isoform and the 
I isoform (Sinha et al., 2009). The most common alternative splicing events have been presented 
in Fig. 1.5, and the nomenclature for alternative splicing events are described below (Table 1.2).   
Five main mechanisms of alternative splicing exist; exon inclusion or skipping, alternative 3’ splice-site 
selection, alternative 5’ splice-site selection, mutually exclusive exons and intron retention. Redrawn and 




Figure 1. 5 A diagram of possible splicing events. 
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Table 1. 2 Description of nomenclature used in splicing events 
 
Nomenclature Description 
∆ x Exon-skipping of exon x 
▼x Intronic retention in intron x 
* Exon-skipping is represented by the symbol ∆, and intron retention is represented by the symbol ▼. 
The numeric value which follows the symbol refers to the exon or intron that is affected. 
 
1.9 Molecular methods for analysing mRNA transcripts 
1.9.1 Polymerase Chain Reaction (PCR) 
PCR is a non-linear amplification method which enables amplification of DNA. Three major 
steps are involved; denaturation, annealing and elongation. The reaction incorporates a DNA 
template, DNA polymerase, forward and reverse 3’ primers, deoxynucleoside triphosphates 
(dNTPs), buffer solution, bivalent cations and monovalent cations (Mullis & Faloona, 1987). The 
method is useful for visualising target samples with small quantities (Erlich, Gelfand, & Sninsky, 
1991). Reverse-transcription PCR is a variation of the PCR concept and works by reverse-
transcribing RNA samples into cDNA.  
 
1.9.2 Quantitative PCR (qPCR) 
This method provides a quantitative assessment of the nucleic acids in the sample of interest. The 
approach provides real-time quantification, where the relative abundance of PCR products can be 
visualised. The approach works by utilising a fluorescent molecule to detect and quantify the 
nucleic acids of interest. There are two main methods of carrying out qPCR; use of intercalating 
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fluorescent dyes which bind non-specifically to double-stranded DNA (Ponchel et al., 2003), and 
the use of a sequence-specific probe with fluorescent molecules which are activated by the 
hydrolytic cleavage by an enzyme (Holland, Abramson, Watson, & Gelfand, 1991).  
 
1.9.3 In vitro transcription  
In vitro transcription is a method of linear amplification of target RNA, which is commonly used 
in situations with a low quantity of starting sample (J. Schneider et al., 2004). The most common 
use of this approach involves a T7 polymerase bacteriophage promoter attached to an oligo-dT 
primer upstream of the sequence to be targeted by the T7 RNA polymerase (Tabor & 
Richardson, 1985). This primes the cDNA strand generated by reverse-transcribing mRNA. This 
amplification is highly reproducible, and the amplified RNA correlates to the total RNA (J. 
Schneider et al., 2004). Furthermore, the average correlation coefficient between in vitro 
amplified and non-amplified samples was shown to be 0.82 (Zhao, Hastie, Whitfield, Borresen-
Dale, & Jeffrey, 2002). Therefore, this approach may be beneficial for visualising poorly 









1.10 Sequencing and genome-wide techniques for studying alternative 
splicing 
1.10.1 Microarrays 
Traditionally, hybridisation microarrays were used to evaluate gene fusion (Lovf et al., 2013), 
mutations/single nucleotide polymorphisms (Park et al., 2004), gene expression (Dhanasekaran 
et al., 2001) and alternatively spliced transcripts (Pan et al., 2004). However, constraints such as 
poor quantification of poorly and highly expressed genes and cross-hybridisation artefacts 
accelerated the development of alternative approaches (Casneuf, Van de Peer, & Huber, 2007; 












1.10.2 First & second-generation sequencing 
Sanger or first-generation sequencing with Expressed Sequence Tags (EST) was widely used 
before the transition into next-generation sequencing or second-generation sequencing (Dias 
Neto et al., 2000). Although Sanger sequencing was regarded as the gold standard, it has a 
relatively low throughput. With the invention of next-generation sequencing, Illumina HiSeq has 
been dominating this field as the new gold standard sequencer with its low cost, high accuracy 
and high throughput properties (Bentley et al., 2008). Furthermore, the Flow Cell Surface 
Reverse Transcription sequencing (FRT-seq) method was developed as an alternative method for 
transcriptome sequencing with the Illumina Genome Analyser. This method uses poly(A)+ RNA 
template as opposed to cDNA template, which maintains strand specificity and reduces PCR bias 
(Mamanova et al., 2010). These methods have been used to define single and multiple exon-
skipping events which occur within a few hundred bases (Colombo et al., 2014; Davy et al., 
2017; Lattimore et al., 2018). However, these methods are suboptimal for examining exon 








1.10.3 Third Generation Sequencing 
The arrival of third generation sequencers with single-molecule detection initiated a new era of 
sequencing, which includes PacBio and nanopore sequencing. Coupled with the ability of real-
time sequencing of single molecules (E. L. van Dijk, Auger, Jaszczyszyn, & Thermes, 2014) and 
long-read sequencing, these two methods are powerful (Hoenen et al., 2016; Rhoads & Au, 
2015). Additionally, the ability of nanopore sequencing to carry out DRS - sequencing of RNA 
as opposed to cDNA offers new potential approaches to understanding RNA splicing (Byrne et 
al., 2017).  
 
 
1.10.3.1 Pacific Biosciences (PacBio) sequencing 
PacBio delivers a fast, long-read, single molecule, third generation sequencing which is able to 
provide data in real-time (Au et al., 2013; Eid et al., 2009; Sharon, Tilgner, Grubert, & Snyder, 
2013). The long reads are suitable for de novo transcriptome assembly (Brown et al., 2014), and 
assessing alternative splicing  This is optimal for analysing and detecting alternative splice 
isoforms due to a higher percentage of complete sequence reads. Hence, the PacBio Iso-Seq 
method has been used to study exon splicing mechanisms and bears a pipeline designed 
specifically for this application (Tabor & Richardson, 1985). However, the inability of carrying 
out DRS and its high error rates (5%) contributes to insertions and deletions and result in the loss 




1.10.3.2 Nanopore sequencing 
Comparatively, nanopore sequencing is a novel technology, derived from the ideas of two 
researchers David Deamer and George Church. The ONT MinION (Figure 1.6 A) is a single-
molecule sequencer similar to the PacBio with the ability to determine exon connectivity in a 
single transcript (Bolisetty, Rajadinakaran, & Graveley, 2015). This is possible even with 
Dscam1, the most complicated alternatively spliced gene known (Bolisetty et al., 2015). The 
flow-cell of a MinION (Figure 1.6 A) consists of a membrane with continuous electrical current, 
in which approximately 2048 nanopores are embedded (Jain, Olsen, Paten, & Akeson, 2016). 
Double-stranded nucleic acids pass one of its strands into the nanopores, disrupting the current 
within the membrane (Kasianowicz, Brandin, Branton, & Deamer, 1996) (Figure 1.6 B). The 
disruption patterns can be attributed to specific bases, and the output data can be analysed further 
via bioinformatic approaches. Unfortunately, this sequencing method also has a high error rate 
(Jain et al., 2016), however, the rolling circle amplification appears to allow improvements in the 
quality (Eid et al., 2009). The approach works by using a circular template to generate a long 
single-stranded DNA or RNA, which can be manipulated to suit the purpose of the experiment 









A                                                       B 
 
A) A diagram of a MinION nanopore sequencer with a flow-cell attached. Each flow-cell carries 
approximately 2048 nanopores. Reproduced from Oxford Nanopore Technologies 
(https://nanoporetech.com/products/minion). B) Figure of a nanopore passing a molecule to be sequenced. 
One strand of the double-stranded molecule bears an anchor to stabilise the structure, in order to allow the 
other strand to penetrate through the nanopore. This allows the nucleic acid to be sequenced. Reproduced 






Figure 1. 6 Parts involved in nanopore sequencing. 
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1.10.3.3 Advantages of nanopore sequencing 
It is now clear that extra benefits are associated with nanopore sequencing compared to PacBio 
other than their mutual long-read sequencing ability. These added advantages include low capital 
cost (Bolisetty et al., 2015), portability, detection of cytosine methylation (Rand et al., 2016; 
Simpson et al., 2017) and DRS ability (Garalde et al., 2018). This may provide more complete 
sequence and modification annotations. Furthermore, the quality of nanopore reads does not 
decline with length, which is advantageous (McCabe, Cormican, Johnston, & Earley, 2018). 
Additionally, the MinION was able to sequence a DNA fragment over 2 million bases, which 
confirms the strength of the sequencer (Payne A, 2018). 
 
Whether in the context of educational institutions or diagnostic clinics, the low capital cost of the 
MinION is advantageous for the end-user. For example, the high capital cost of PacBio 
sequencing deters institutions and clinics from implementing its long-read ability (Bolisetty et 
al., 2015). In contrast, the MinION has the lowest costs among all single molecule sequencers 
(Rhoads & Au, 2015).  
 
Portability allows the MinION to be utilised in in-field diagnostics, unlike other sequencers (Jain 
et al., 2016). The MinION was used during the Ebola and Zika outbreaks and thus its usefulness 
has been well validated (Quick et al., 2017; Quick et al., 2016). Similarly, it was implemented in 
rapid bovine pathogen diagnostics, increasing the feasibility of this technology to be applied in 




Overall, the high consensus among studies suggests that the biggest drawback of using nanopore 
sequencing is the high error rate. Nanopore sequencing has difficulties with high G + C content 
sequences (Laver et al., 2015), homopolymer tracts (Loman, Quick, & Simpson, 2015), and low 
base-call accuracy (Faucon et al., 2017; McCabe et al., 2018). To illustrate the severity of this 
issue, 1D (template strand) error rates of > 20 % and 2D (template and complement strands) 
error rates of 10-15 % were noted in 2016 (Ip et al., 2015). Nevertheless, improvements in 
accuracy and throughput have occurred over the past few years and are likely to continue 
(Bolisetty et al., 2015). The use of Unique Molecular Identifiers may improve the variation in 
transcript quantification (Islam et al., 2014). Contrastingly, another disregards the feasibility of 
this approach as the length of the Unique Molecular Identifiers is required to be > 30 bp with the 
current state of errors (Byrne et al., 2017). It is suggested that base-calling algorithms need to be 
improved to further address this problem and software need to be optimised for nanopore 
sequencing (Garalde et al., 2018). Furthermore, as the motor-DNA complex determines the read 
length and accuracy, searching for more sophisticated motor proteins with longer processivity in 









1.11 RNA-seq vs Direct RNA Sequencing (DRS)  
It is evident that there had been an ongoing effort to deliver the best version of RNA-Seq 
technology. The perpetual drive for creating superior RNA-Seq technology derives from the fact 
that this technology is useful and may be applied to various research studies (Dillies et al., 2013). 
The term 'RNA-Seq' has been well incorporated into scientific literature, however, the term has 
become a misnomer with the advancement of sequencing technology. While countless older 
studies have used 'RNA-Seq' as a term for direct sequencing of cDNA, the term was incorrectly 
accepted as an accurate term because DRS was not possible. However, the advent of DRS has 
made the use of this term problematic, where recent studies have had to implement the term 
'direct RNA-Seq' to distinguish from ‘RNA-Seq’. However, certain studies use these two terms 
interchangeably, which defeats the purpose of distinguishing these two terms (Q. Xu et al., 
2017). Thus, it is important that these terms are used appropriately. 
 
RNA-Seq reads cDNA molecules which has been reverse-transcribed from an RNA sample, and 
the generated reads are aligned to a reference genome for further analysis (Soneson & Delorenzi, 
2013). This method has been utilised for de novo assembly of transcripts (Cao et al., 2015), 
studying the transcriptome (Nagalakshmi et al., 2008), gene expression studies (Zhuo, Emerson, 
Chang, & Di, 2016) and detecting alternative splicing isoforms (Davy et al., 2017). 
Bioinformatic analysis is efficient with RNA-seq as more tools have been developed for RNA-
seq compared to DRS. However, limitations include error propagation (Roberts et al., 1989), 
artificial splicing (Cocquet, Chong, Zhang, & Veitia, 2006), duplication errors (Salzberg  et al., 
2017) and loss of strandedness information (Haddad, Qin, Giger, Guo, & Baldwin, 2007). Long 
transcripts are also over-represented compared to shorter transcripts, which poses a statistical 
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bias (Oshlack & Wakefield, 2009). Problems with analysing complex genomic regions, isoform 
detection and identifying methylations also exist specifically with short-read RNA-seq (Byrne et 
al., 2017; Rhoads & Au, 2015). The uneven coverage along the genome is problematic as the 
differences in the sequencing depths are troublesome (Soneson & Delorenzi, 2013). However, 
methods to mitigate the loss of strandedness are available (Chu & Corey, 2012), and alternative 
splicing analyses, computational approaches and repetitive sequencing can compensate the bias 
effect (Oshlack & Wakefield, 2009), but at the cost of increasing the cost per base for a given 
accuracy rate.  
 
In contrast, the main advantage of DRS is its ability to sequence RNA without the need for 
converting to cDNA prior to sequencing. Microarrays and RNA-Seq techniques required this 
cDNA conversion step as RNA was not able to be sequenced directly (Aird et al., 2011). The 
elimination of the reverse transcription, ligation and amplification steps is advantageous as it 
minimises the distortion RNA template representation (Ozsolak & Milos, 2011a). DRS only 
requires 3′ polyadenylated templates to allow short and long RNAs to be sequenced together in a 
single experiment (Ozsolak & Milos, 2011b). These advantages simplify the overall workflow 
and reduce reagent costs. Long-read DRS is necessary to gain enough coverage at 5' and 3' ends 
to identify full-length transcripts, which cannot be reciprocated in conventional RNA-Seq (Levin 
et al., 2010). This method will also allow detection of nucleotide analogues, reduction of PCR 
bias, and strand specificity (Salzberg  et al., 2017). Finally, fusion events and RNA modifications 
can also be visualised with this method (Garalde et al., 2018).  One limitation is lower base-
calling accuracy with DRS compared to RNA-Seq (Garalde et al., 2018). Nonetheless, as with 
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improvements in RNA-Seq, rapid optimisation is expected to occur with growing interest in DRS 
methods.   
 
1.12 Analysis 
The basic flow of downstream sequencing analyses is similar between all next-generation 
sequencing and third-generation sequencers. Sequencing with next-generation sequencing and 
single molecule platforms create FASTQ-format files for the generated reads. These reads are rid 
of sequencing artefacts and errors, aligned to reference genomes, annotated and quantified (Chu 
& Corey, 2012). Short-read sequencers with limited ability to recognise exon connectivity in 
mRNAs have been coupled with software programmes to account for this constraint (Bolisetty et 
al., 2015). However, examining exon co-occurrence in BRCA1 transcripts has been shown to 
overcome this problem with the use of the MinION (de Jong et al., 2017). Bioinformatic tools 
are available from ONT, and many are also developed by the community which are freely 
accessible via online repositories (Chu & Corey, 2012). As nanopore technology is a relatively 
novel concept, the topic of optimum bioinformatic software for downstream analyses is well 
debated. Overall, as it is difficult to determine the best progression of bioinformatic software 
associated with the MinION, tools should be carefully selected depending on the application.  
 
All RNA-Seq and DRS approaches display advantages and disadvantages, and this suggests that 
it is best to select sequence platforms based on the downstream application (Soneson & 
Delorenzi, 2013). If higher accuracy is a priority over the ability to examine alternative splicing, 
traditional methods should be used over single-molecule based platforms (Chu & Corey, 2012). 
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However, nanopore sequencing appears to be the best overall approach to study VUS effects on 
alternative splicing patterns of RNA transcripts due to its long-read, high throughput, and DRS 
capabilities.  
 
1.13 Aims and Hypotheses 
The primary hypothesis of this project was that the MinION nanopore sequencer can directly 
read and detect full-length RNA isoforms of BRCA1. A secondary hypothesis was that a novel 
enrichment method is able to linearly amplify RNA isoforms in a quantitative manner by in vitro 
transcription. The aims of this project are to develop and test a novel approach for linear 
enrichment of RNA transcripts from a control lymphoblastoid cell line (LCL) and to quantify the 
different isoforms, which will be valuable in understanding any splicing alterations caused by 
VUS. Nanopore sequencing is a relatively new technique and testing its parameters and using 









Chapter 2: Materials and Methods 
 
 
Table 2. 1 List of products and reagents used in experiments 
Name of Product/Reagent Manufacturer/Source Location 
Tris Base Thermo Fisher Scientific Massachusetts, United States  
EDTA Ajax Finechem by Thermo 
Fisher Scientific 
Auckland, New Zealand 
Glacial Acetic Acid Thermo Fisher Scientific Massachusetts, United States 
Lymphoblastoid Cell Line 
(07.111.0085) 
kConFab Melbourne, Australia 
Cycloheximide Solution Sigma-Aldrich Missouri, United States 
Fetal Bovine Serum Hyclone™ (GE Life 
Sciences) 
Auckland, New Zealand 
Penicillin/Streptavidin Gibco® by Life 
Technologies™ 
Auckland, New Zealand 
RPMI Medium 1640 1X 
(+ L-Glutamine) 
Gibco® by Life 
Technologies™ 
 
Auckland, New Zealand 
RNeasy® Mini Kit Qiagen Hilden, Germany 
polyA-Spin™ mRNA 
Isolation Kit  
New England BioLabs® Inc. Massachusetts, United States 
NanoDrop™ 8000 
Spectrophotometer 
Thermo Fisher Scientific Auckland, New Zealand 
Qubit™ RNA HS Assay Kit Invitrogen by Thermo Fisher 
Scientific 
Oregon, United States 
Qubit™ 1X dsDNA HS 
Assay Kit 
Invitrogen by Thermo Fisher 
Scientific 





Agilent Technologies California, United States 
Primers Integrated DNA 
Technologies 
Queenstown, Singapore 
RNAseZap™ Invitrogen by Thermo Fisher 
Scientific 
Vilnius, Lithuania 
Superscript® III Reverse 
Transcriptase 
Invitrogen by Thermo Fisher 
Scientific 
California, United States 
Ambion™ RNAseH, E.coli Invitrogen by Thermo Fisher 
Scientific 
Vilnius, Lithuania 
RNAseA/T1 Mix Thermo Scientific Massachusetts, United States 
Betaine Thermo Fisher Scientific Massachusetts, United States 
KAPA 5X Long Range 
Buffer 
KAPA Biosystems Massachusetts, United States 
25 mM MgCl2 KAPA Biosystems Massachusetts, United States 
10 mM dNTP mix KAPA Biosystems Massachusetts, United States 
KAPA Long Range Hotstart 
(2.5 U/µL) 
KAPA Biosystems Massachusetts, United States 
Fisher TAQ-Ti DNA 
Polymerase (5 U/ µL) 
Fisher Biotec Wembley, Australia 
Fisher TAQ-Ti DNA 
Polymerase 10X Reaction 
Buffer 
Fisher Biotec  Wembley Australia 
Nuclease-Free Water - 
UltraPure™ Distilled Water 
Gibco® Invitrogen Auckland, New Zealand 
HyAgarose™ HydraGene New Jersey, United States 
SYBR® Safe DNA Gel Stain Invitrogen by Thermo Fisher 
Scientific 
California, United States 
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Electrophoresis System – 
PowerPac Basic™ (300 
V/400 mA/75 W) 
BIO-RAD California, United States 
KAPA Universal DNA 
Ladder 
KAPA Biosystems Massachusetts, United States 
 
6X KAPA Loading Dye KAPA Biosystems Massachusetts, United States 
 
Alliance 4.7 Imaging System  UVItec Cambridge, United Kingdom 
LongAmp® Taq PCR Kit  New England BioLabs® Inc. Massachusetts, United States 
HighPrep™ PCR Magnetic 
Beads 
MAGBIO Genomics Inc.  Maryland, United States 
MEGAscript™ T7 
Transcription Kit 
Invitrogen by Thermo Fisher 
Scientific 
Vilnius, Lithuania 
RNAClean™ XP Beckman Coulter® California, USA 
MinION Flow-Cell – FLO-









1.7 mL Clear Microtubes Axygen® California, United States 
RNAseOUT™ Invitrogen by Life 
Technologies 
California, United States 









2.1 General stocks 
2.1.1 Tris/Acetic acid/EDTA (TAE) buffer  
A solution of 10 X TAE buffer was made with 48.4 g of Tris Base, 3.7 g of EDTA, and 11.4 mL 
of glacial acetic acid. The solution was made up to 1 L with MilliPore Water (MPW). The buffer 
was diluted to 1x for further use.  
 
2.1.2 Tris/EDTA (TE) buffer   
TE buffer was formulated by adding 1 mL of 1 M Tris Base, and 200 µL of 0.5 M EDTA, to a 
final volume of 100 mL with MPW. The final concentrations of the solution comprised of 10 
mM of Tris Base, and 1 mM EDTA.  
 
2.2 RNA source/cell culturing 
A control LCL (07.111.0085) was grown in 37 °C and 5 % CO2 incubation, suspended in 20 µL 
of media. Media used to culture the cells consisted of 55 mL of Fetal Bovine Serum, 5.5 mL of 
Penicillin/Streptavidin and 500 mL of RPMI 1640. Cells were fed and split into new passages 
every 1-3 days.  
 
Shortly before RNA extraction, the cells were treated with cycloheximide solution (NMD 
inhibitor) for 4 hours. The cultured cells were used to extract total RNA via the RNeasy® Mini 
Kit according to the protocol described in Appendix A. Twenty-three RNeasy® Mini Kit 
extractions were performed in total. PolyA-Spin™ mRNA Isolation Kit was used to isolate the 
mRNA according to the protocol described in Appendix B. One PolyA-Spin™ mRNA Isolation 
Kit extraction was performed in total. NanoDrop™ 8000 Spectrophotometer, Qubit™ RNA HS 
Assay Kit and the Agilent RNA ScreenTape/Tapestation were used to determine the quality and 
concentration of the extracted RNA.  
35 
 
2.3 Primer design 
The software Primer 3 (version 0.4.0) and Geneious (version 11.1.4) were used for designing primers (Table 2.2).  
 
 
Table 2. 2 List of primers designed for PCR reactions, with characteristics 
 
Name 






















































































53.0 T7 polymerase binding site attached to a BRCA1 exon 1 forward primer  
 
T7_F  GGTAATACGACTCACTATAGGGAGA 
 
54.6 T7 polymerase binding site forward primer 
Anchored 
Oligo-dT(20) 
TTTTTTTTTTTTTTTTTTTTVN 41.0 Oligo-dT20 primer with a TN anchor  




68.1 BRCA1 exon 1 forward primer  
BRCA1_24p
R 
AAGCTCATTCTTGGGGTCCT 56.2 BRCA1 exon 24 reverse primer on the p side 
 





2.4 First cDNA strand synthesis 
Preparation of cDNA was executed in a pre-PCR room free of post-PCR contaminants. 
RNAseZAP™ was used to clean workbenches and pipettes to minimise RNAse contamination. 
RNA extracted from the control LCL was reverse-transcribed using the enzyme Superscript® III 
Reverse Transcriptase according to the protocol described in Appendix C. An aliquot of this 
cDNA sample was diluted 1:5 with NFW for use in quality control tests.   
 
An anchored oligo-dT(20) was utilised instead of a standard oligo-dT(20) primer as it carries a TN 
anchor, which allows it to bind exactly to the end of the 5’ of the poly-A tail of mRNA (Nam et 
al., 2002). This minimizes the binding to internal intronic poly-A sites, which was likely to 
reduce spurious transcription events.  
 
2.4.1 Quality control for first cDNA strand synthesis 
2.4.1.1 Standard long-range PCR  
All standard long-range PCR reactions were made to a total reaction volume of 20 µL. Each 
reaction contained 1.3 M betaine, 1x KAPA long range buffer, 1.75 mM of MgCl2, 0.5 μM of 
each forward and reverse primer (BRCA1_1F and BRCA1_24pR respectively), 300 μM of KAPA 
10mM dNTP mix, 0.5 units of KAPA Long Range HotStart and 1.2 µL of 1:5 diluted cDNA.  
Thermal cycling conditions consisted of an initial denaturation step of 94 °C for 4 minutes, then 
35 cycles of 94 °C denaturation step for 30 seconds, a 59 °C annealing step for 30 seconds, and 




2.4.1.2 Alternative long-range PCR  
The alternative long-range PCR was carried out to carry out an improved method of long-range 
PCR. This PCR consisted of a higher MgCl2 and cDNA concentration, lower dNTP 
concentration and lower denaturation and extension times compared to the standard long-range 
PCR. All alternative long-range PCR reactions were made to a total reaction volume of 10 µL. 
Final reactions contained 1 M betaine, 1x KAPA long range buffer, 2 mM of MgCl2, 0.7 μM of 
each forward and reverse primer (BRCA1_1F and BRCA1_24pR respectively), 200 μM of 
KAPA 10 mM dNTP mix, and 0.5 units of KAPA Long Range HotStart, and 3 µL of 1:5 diluted 
cDNA. Thermal cycling conditions consisted of an initial denaturation step of 94 °C for 2 
minutes, then 35 cycles of 94 °C denaturation step for 30 seconds, a 59 °C annealing step for 30 
seconds, and an extension step at 68 °C for 7 minutes, with a final extension of 72 °C for 7 
minutes. 
 
2.5 Second cDNA strand synthesis 
The LongAmp® Taq DNA Polymerase kit was used to generate the second cDNA strand. A 
Gene Specific Primer (GSP) attached to a T7-polymerase binding site was used to generate the 
second strand of cDNA with this kit, according to the modified protocol (Appendix D). The 
modifications include the number of PCR cycles and using an optimum annealing temperature. 
The manufacturer recommends an annealing temperature ranging from 45 to 65 °C 
(https://international.neb.com/protocols/2012/10/15/m0323-longamp-taq-dna-polymerase-
protocol). Therefore, a temperature gradient PCR was carried out to determine the optimum 
annealing temperature for the T7-GSP primer for BRCA1 and GAPDH.  
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2.5.1. Temperature gradient PCR 
Temperature gradient PCR was carried out to find the optimal annealing temperature for second 
strand cDNA synthesis. All temperature gradient reactions consisted of 12 reactions of 10 µL. 
T7-BRCA1 exon 1 forward and exon 7 reverse primers were used for BRCA1, and T7-GAPDH 
exon 1 forward and exon 9 reverse primers were used for GAPDH. Each reaction volume 
comprised of 1x TAQ buffer, 0.1 mM dNTP mix, 1.5 mM MgCl2, 0.5 units Fisher TAQ-Ti DNA 
polymerase, 0.5 µM forward primer, 0.5 µM reverse primer, 1 mM betaine, and 1 µL of 1:5 
dilution cDNA, with the rest of the reaction volume made up to 10 µL with NFW. The cycling 
conditions were 1 cycle of 94 °C for 2 minutes, 45 cycles of 94 °C for 15 seconds, 50-65 °C 
gradient across 12 lanes for 15 seconds, 72 °C for 2 minutes, 1 cycle of 94 °C for 5 minutes and 
a final step of 1 cycle of 25 °C for 2 minutes.  
 
2.5.2 Quality control for second cDNA strand synthesis 
2.5.2.1 T7-only primer PCR 
Products generated from cDNA second strand synthesis in experiment 4 were tested using the 
T7-only primer and a respective reverse primer to visualise the incorporation of the T7-GSP. The 
T7 only primer and BRCA1 exon 7 reverse primer were used for BRCA1, and T7 only primer and 
GAPDH exon 9 reverse primer were used for testing GAPDH. All reactions were made up to a 
total volume of 20 µL. Each reaction volume consisted of 1x Fisher buffer, 0.2 mM dNTP mix, 
1.5 mM MgCl2, 0.5 units Fisher TAQ-Ti DNA polymerase, 2 µL of dscDNA, 0.5 µM T7-only 
forward primer, 0.5 µM reverse primer, 1 M betaine, and the rest of the reaction volume made up 
to 20 µL with NFW.  The cycling conditions were 1 cycle of 94 °C for 2 minutes, 45 cycles of 94 
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°C for 15 seconds, 50 °C for 15 seconds, 72 °C for 2 minutes, 1 cycle of 94 °C for 5 minutes and 
1 cycle of 25 °C for 2 minutes.  
 
2.5.2.2 T7-only and oligo-dT(20) primer (full-length) PCR 
Products of the cDNA second strand synthesis were tested using the T7-only and an oligo-dT(20) 
primer in experiment 4. All reactions were made up to a total volume of 20 µL. Each reaction 
volume consisted of 1x Fisher buffer, 0.2 mM dNTP mix, 1.5 mM MgCl2, 0.5 units Fisher TAQ-
Ti DNA polymerase, 2 µL of dscDNA, 0.5 µM T7-only forward primer, 0.5 µM oligo-dT(20) 
reverse primer, 1 M betaine, and the rest of the reaction volume made up to 20 µL with NFW.  
The cycling conditions were 1 cycle of 94 °C for 2 minutes, 45 cycles of 94 °C for 15 seconds, 
50 °C for 15 seconds, 72 °C for 2 minutes, 1 cycle of 94 °C for 5 minutes and 1 cycle of 25 °C 
for 2 minutes.  
 
2.6 Agarose gel electrophoresis 
Agarose gels (1 % in TAE) were used for visualising all PCR products. Agarose powder was 
dissolved in 1x TAE buffer and 1 µL of SYBR® Safe DNA Gel stain was added for each 25 mL 
of 1x TAE buffer used. This gel was set in a PowerPac Basic™ electrophoresis system, which 
was submerged in 1x TAE buffer. 4 µL of KAPA Universal DNA ladder was loaded into the 
first lane. 1x volume of 6x KAPA loading dye was added to each PCR product and loaded on the 
gel. Electrophoresis was carried out with the electrophoresis system at 90 V for 30-60 minutes. 
The gel was examined via the image system Alliance 4.7.  
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2.7 HighPrep™ magnetic bead clean-up 
HighPrep™ magnetic beads were used to isolate dscDNA from the products of the cDNA 
second-strand synthesis according to the protocol described in Appendix E.  
 
2.8 In vitro transcription 
The MEGAscript™ T7 Transcription Kit was used to generate RNA via in vitro transcription 
according to the protocol described in Appendix F. The extension was run for 4 hours in 
experiment 2, 16 hours in experiment 3 and 20 hours in experiment 4. The quality of the in vitro 
transcribed RNA was checked via the Tapestation assay.  
  
2.9 RNAClean™ XP magnetic bead clean-up 
The RNAClean™ XP beads were used to isolate the RNA products from the in vitro 
transcription step in experiment 4, according to the protocol described in Appendix G. In 
experiment 4, 20 µL of RAD51C, BRCA1, CHEK2 in vitro products and 1 µL of GAPDH in vitro 
product were pooled and cleaned with the RNAClean™ XP beads, and eluted with 15 µL of 





2.10 MinION library preparation and sequencing 
The protocol for library preparation was as described by Oxford Nanopore Technologies 
(protocol version: DRS_9026_v1_revN_15Dec2016), which is in Appendix H. The kit control 
was omitted in the reaction and was replaced with the same volume with in vitro transcribed 
RNA, which was isolated by the RNAClean™ XP beads and reverse-transcribed as a part of the 
protocol, and then adapters were ligated to the mRNA (Figure 2.1). The same Direct RNA 
Sequencing Kit was used in all experiments (SQK-RNA001), and all flow-cells were checked for 




The steps involved are; primer annealing and ligation, reverse transcription, attachment of 1D sequencing 
adapters and dual tethers, and loading this resulting sample on a flow-cell. These steps ensure that the 
mRNA molecule is able to be sequenced by the nanopores.  Reproduced from 
https://store.nanoporetech.com/direct-rna-sequencing-kit.html. 
Figure 2. 1 A brief schematic of library preparation with the ONT Direct RNA Sequencing Kit. 
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2.11 MinION sequencing analysis 
2.12.1 Basic data acquisition 
MinKNOW is the default software developed by ONT for the purposes of carrying out data 
acquisition, data streaming, real-time analysis and feedback, and sample identification and 
tracking (https://nanoporetech.com/analyse). MinKNOW version 1.13.1 and 1.14.1 (Table 2.3) 
were used to derive FAST5 files from the ONT MinION sequencing reads from experiment 1 
and experiments 2-4 respectively. The concatenated FAST5 files were basecalled via Albacore 
version 2.3.0, a basecalling software which identifies DNA/RNA sequence information from the 
raw data from the MinKNOW programme (https://nanoporetech.com/about-us/news/new-
basecaller-now-performs-raw-basecalling-improved-sequencing-accuracy). The basecalling was 
carried out with the command ‘nice read_fast5_basecaller.py --input [pathway to fast5 files] --
worker_threads 4 --save_path [pathway and name of output files] --flowcell FLO-MIN106 --kit 
SQK-RNA001 --output fastq --recursive --files_per_batch_folder 0’. This created FASTQ output 
files. The reads were then concatenated with the script ‘cat *fastq > filename.fastq’. This created 
concatenated FASTQ files. Total counts of reads were calculated via the command ‘awk ‘{s++} 










Table 2. 3 List of programmes used for basic data acquisition 
Programme Source 












2.12.2 Alignment  




Human Genome hg38 http://hgdownload.soe.ucsc.edu/goldenPath/hg3
8/bigZips/ 
GRCh38.12 Human Genome Reference Build hg38 






Genome compiled by Dr. Heng Li (Broad Institute) - more suitable for the 




Gencode v28 (GRCh38.12) 
Reference_panel_genes.fasta https://www.ncbi.nlm.nih.gov/ File of FASTA sequences from all genes studied in this thesis 
Gencode v28 annotation 
GFF3 file  
https://www.gencodegenes.org/releases/current.
html 
Gencode v28 (GRCh38.12) annotation GFF3 file 
BRCARD1_geneseq.fasta Reference taken from the storage file of Gene 
Structure and Function Laboratory (GSFL), 
University of Otago, Christchurch 
File of joined FASTA sequences of BRCA1 and BARD1. Prepared by Lucy de 
Jong (GSFL). 




DRS data generated by an international Nanopore RNA Consortium with RNA 
isolated from a lymphoblastoid cell line (NA12878) 






A subset of DRS data generated by an international Nanopore RNA Consortium 
with RNA isolated from a lymphoblastoid cell line (NA12878). This consists of 
pass reads from one MinION run (Notts_Run1). 
Makenzie Cancer Research 
Group (MCRG) RNA-seq 
data 
Appendix I  File of a subset of RNA-seq data generated in the Mackenzie Cancer Research 
Group (MCRG) with a control LCL (08.111.0064) 
Davy et al. (2017) data Supplementary table 1 from Davy et al. (2017) Table of BRCA1, RAD51C, CHEK2 alternative splicing events observed in 
RNA-seq data from Davy et al. (2017)  
 




2.12.2.1 Alignment with Minimap2 
Minimap2 (Table 2.5) is a pairwise aligner for genomic and spliced nucleotide sequences, which 
has specific parameters for nanopore DRS reads (H. Li, 2018b). The aligner Minimap2 was used 
to index various reference genomes (Table 2.4) with commands ‘minimap2 -d ref.mmi 
[reference file].fasta’. These indices were used to align our concatenated FASTQ files mainly 
with the commands ‘minimap2 -ax splice -uf -k14 [pathway to index file] [input files].fasta > 
[output file].sam’. SAM files were created through this alignment, and different parameters were 
also tested during this step. From these SAM files, BAM files were created with the commands 
‘samtools view –S –b [pathway to file].sam > [pathway and name of output file].bam’, sorted 
with the commands ‘samtools sort [pathway to file].bam –o [pathway and name of input 
file].sorted.bam’, and indexed with the commands ‘samtools index [pathway to sorted file].bam’. 
The sorted BAM files were visualized on the Integrated Genomics Viewer (IGV) version 2.4.  
 
2.12.2.2 Alignment with BLAST-Like Alignment Tool (BLAT) 
BLAT (Table 2.5) is a rapid alignment tool which is commonly used for mRNA/DNA and cross-
species protein alignments (Kent, 2002). The concatenated FASTQ file was converted to FASTA 
files via the command ‘seqtk seq -a in.fastq.gz > [output file].fasta’. The aligner BLAT was used 
to align our FASTA files to various reference genomes with a range of parameters. PSLX and 
BLAST8 files were created as a result. After these files were checked via Microsoft Office Excel 
2013, the PSLX files were converted into SAM files with the psl2sam.pl script, which were then 
in turn converted to BAM files. The BAM files were sorted and indexed with the programme 
Samtools, and visualized on IGV version 2.4. 




2.12.2.3 Alignment with Genomic Mapping and Alignment Programme 
(GMAP) 
GMAP (Table 2.5) is generally used for mRNA and EST sequences (T. D. Wu & Watanabe, 
2005). The concatenated RNA FASTQ files were converted to FASTA files via the command 
‘seqtk seq –a in.fastq.gz > [output file].fasta’. The FASTA files were converted to cDNA via 
converting Uracils to Thymines by the GALAXY FASTA Manipulation RNA/DNA Converter. 
The cDNA FASTA file was then used for GMAP alignment. 
 
2.12.2.4 Alignment with LAST  
LAST (Table 2.5) was designed for aligning long RNA or DNA reads (M. C. Frith, Wan, & 
Horton, 2010). The LAST databases were created by the command ‘lastdb -P8 -uNEAR -R01 
mydb [path to reference genome/transcriptome file].fasta’. This created FASTA files. The 
query files were aligned with the commands ‘parallel-fasta ‘lastal -p myseq.par -d90 -m50 -D10 











Table 2. 5 List of programmes used for alignment 
Programme Source 
Minimap2 - v2.11-r819-dirty https://github.com/lh3/minimap2#install 
BLAT - v36 x 2  http://www.blat.net/examples/install&profile.html 
GMAP - v2016-09-23 http://research-pub.gene.com/gmap/ 
LAST - v941 https://github.com/mcfrith/last-rna/blob/master/last-long-
reads.md 























2.12.3 Quantification  
2.12.3.1 Isoform Counts with Kallisto 
Kallisto (Table 2.6) is a programme for quantifying reads generated from high throughput RNA-
seq experiments (N. L. Bray, Pimentel, Melsted, & Pachter, 2016). Kallisto index files were 
created with a reference transcriptome (Table 2.4) via the commands ‘kallisto index –i [pathway 
to output file] [reference transcriptome].fasta’. The index was then used to quantify the different 
transcripts produced by the MinION run, using the concatenated FASTQ files. The command 
used was 'kallisto quant –i [pathway to index file] -o [pathway to output directory] --single –l 
[mean read length] -s [standard deviation of reads] [pathway to query file].fastq --bias –t 4’. This 
produced a TSV file including the name, length, effective length, estimated counts and 
Transcripts Per Million (TPM), which were visualised via Microsoft Office Excel 2013. The 
mean read length and standard deviation of reads were generated by the StatsFasta.py script 











2.12.3.2 Isoform Counts with Salmon 
Salmon (Table 2.6) is a programme for rapid quantification of transcripts from RNA-seq 
experiments (R. Patro, G. Duggal, M. I. Love, R. A. Irizarry, & C. Kingsford, 2017). Various 
parameters of Salmon were used to test its ability to quantify ONT DRS reads. Quasi-non-
aligned-based mode was tested by creating an index with the commands ‘salmon index –t [path 
to reference transcriptome].fa -i transcripts_index  --type quasi –k 31’. The index was used to 
quantify with the commands ‘salmon quant -i  [pathway to index file] -l A --fldMean [mean read 
length] --fldSD [standard deviation of reads] -r [pathway to query file].fastq -o [name of output 
file]’. The mean read length and standard deviation of reads were generated by the StatsFasta.py 
script (Table 2.6). Non-quasi alignment-based mode was tested with the commands ‘salmon 
quant –t [pathway to reference transcriptome].fa -l A –a [pathway to minimap2-aligned 
bam/sorted.bam file].bam -o [name of output file]’. The two methods produced an SF file as a 
result including names, length, effective length, Transcripts Per Million (TPM) and number of 










2.12.3.3 Isoform Counts with Mandalorion – Episode II 
Mandalorion – Episode II (Table 2.6) is a pipeline which determines how many reads overlap 
with the exons of a gene to produce a reads/gene per 10,000 reads (R. Volden et al., 2018; R.  
Volden & Vollmers, 2018). The commands ‘python3 defineAndQuantifyWrapper.py -c [path to 
content_file] -p [path to query file] -u 5 -d 30 -s 200 -r 0.05 -R 3 -i 0 -t 0 -I 100 -T 60 -g [path to 
gencode v28 annotation GTF file] -m NUC.4.4.mat -f [patht to example_config file]’ were used to 
align the output of the MinION DRS parameters, which were the exemplar experiments given by 
the Mandalorion creators. 
 
 
2.12.3.4 Isoform Counts with Structural and Quality Annotation of Novel 
Transcript Isoforms (SQANTI) 
SQANTI (Table 2.6) is a pipeline which was created specifically to characterise PacBio cDNA 
long reads (de la Fuente & Tardaguila, 2018). Various parameters were tested with SQANTI, 
with alignment to either the human genome or the human transcriptome. SQANTI utilised 
GMAP databases, which were already created from the alignment steps in chapter 2.12.2.3. The 
general command used was ‘sqanti_qc.py -x [path to GMAP database] -o [name of output file] -d 
[path to output directory] [query file].fasta [annotation file].gtf [reference file].fasta’. 
 
 




2.12.3.5 Isoform counts with manual quantification 
BRCA1, CHEK2, RAD51C and GAPDH transcripts including full-length and non-full-length 
isoforms were counted manually from the sorted BAM file being visualised on IGV. The counts 
were organised into a table of counts. These counts were compared to counts generated from 
external datasets which include, DRS data from the Nanopore RNA Consortium, RNA-seq data 
from Mackenzie Cancer Research Group and RNA-seq data from a study by Davy et al. (2017) 
(Table 2.4). Initially, a subset of nanopore pass reads (Consortium Subset Data) from the 
Nanopore RNA Consortium were aligned and manually quantified due to the interest of time and 
lack of satisfactory analysis software. Subsequently, the full dataset was aligned with Minimap2 
and quantified manually (including RAD51C, BRCA1 and CHEK2). The GAPDH reads from the 
full dataset were not counted due to an interest of time, hence the subset data was used for 
downstream analysis for GAPDH transcripts.  
 
 
Table 2. 6 List of programmes used for quantification 
Programme Source 
Kallisto-v0.44.0  http://pachterlab.github.io/kallisto/download 
Salmon-v0.11.2 https://github.com/COMBINE-lab/salmon/releases 









Chapter 3: Direct RNA sequencing of total Poly-A 
RNA (Experiment 1) 
 
3.1 Introduction 
For this project, four independent successive experiments (named Experiment 1-4) were carried 
out, each one involving development and analysis of an RNA library on a MinION flow-cell 
(Figure 3.1). Experiment 1 was carried out as the control experiment, by sequencing poly-A 
RNA isolated from a control LCL. In experiment 2, GAPDH was utilised as a control gene and 
was also enriched and sequenced along with BRCA1. In experiment 3, BRCA1 and 11 
other hereditary breast and ovarian cancer genes with a range of different transcript lengths and 
expression levels were utilised to test the enrichment with this novel enrichment technique. In 
experiment 4, GAPDH, BRCA1, CHEK2 and RAD51C were used to test the enrichment 
technique. The purpose of the control experiment was to establish the DRS library preparation 
procedures in this laboratory, and to test the ability of the MinION to successfully carry out 
DRS. The data generated from this experiment was used as a control reference dataset to observe 
findings in subsequent experiments.  
 
 





Experiment 1 utilised an mRNA isolation step, which was not employed in the other three experiments. 
Each experiment involved an RNAClean™ XP magnetic bead clean-up step as a part of the MinION 
library preparation. However, an extra magnetic pooling step with the RNAClean™ XP beads was carried 
out in experiment 4. All experiments consisted of cell culture, RNA extraction, MinION library 
preparation, MinION sequencing, alignment and quantification. Experiments 2-4 also included 1st and 2nd 
cDNA strand synthesis, clean-up with HighPrep™ magnetic beads and in vitro transcription.  
 
Experiment 1 Experiments 2-4 
Figure 3. 1 A schematic diagram of the sequence of methods used in all experiments. 




3.2 RNA source/cell culturing 
A control LCL was grown within RPMI 1640 media in suspension culture. After cycloheximide 
treatment, total RNA was extracted from these cells with the RNeasy® Mini Kit. The RNeasy® 
Mini Kit preparations were carried out 8 times for this experiment. The extracted total RNA 
presented with satisfactory quality from NanoDrop™, Qubit™ RNA HS and Tapestation results. 
Tapestation results were consistently above an RNA Integrity Number equivalent (RINe) score 
of 9.3. NanoDrop™ and Qubit™ results varied across the 8 RNA extraction events. Then, the 
RNA from 8 extractions were pooled to increase the concentration per given volume. The 
average NanoDrop™ concentration was 934.68 ng/µL and the average Qubit™ RNA HS result 
was 402.86 ng/µL. Poly-A RNA was isolated from the total RNA, using the polyA-Spin™ 
mRNA Isolation Kit. This step was carried out once, and Qubit™ RNA HS result from this 
mRNA isolation step revealed a concentration of 7.56 ng/µL and a total amount of 151.2 ng in a 
20 µL volume.  
 
3.3 MinION sequencing and bioinformatic analyses 
The ONT protocol for the DRS kit was used according to the protocol described in Appendix H. 
The library preparation steps involved using the Direct RNA Sequencing Kit to prepare the 
mRNA for sequencing. This consisted of annealing and ligating the primers, reverse-
transcription, attachment of 1D sequencing adapters and dual tethers (Figure 2.1). The prepared 
library was loaded on a MinION flow-cell, and sequencing was carried out for 48 hours. The 
total number of 889,850 sequenced reads was acquired by MinKNOW v1.13.1. Albacore v2.3.0 
was used to basecall these reads and generate FASTQ files. This produced ‘pass’ and ‘fail’ 




folders, which contained 539,776 and 104,902 FASTQ reads respectively. All FASTQ files in 
the ‘pass’ folder were concatenated.  
 
3.3.1 Alignment of MinION-generated reads 
The concatenated FASTQ files from the data acquisition step were attempted to be aligned to 
various alignment programmes, by testing different parameters (Tables 3.1-3.9). 




Using Minimap2, the parameters ‘k’ and ‘G’ were examined with the compiled Human Genome hg38 (Table 2.4). The ‘G’ parameter 
sets the maximum intron length, and the ‘k’ parameter sets the k-mer size (H. Li, 2018a). Each index was used to align FASTQ files to 
the compiled Human Genome hg38 with Minimap2, and the resulting SAM file was converted to BAM, sorted and indexed with 
Samtools, to be visualised on IGV. The results revealed no major differences between the successful indices, hence default parameters 
















Table 3. 1 Comparison of parameters ‘k’ and ‘G’ for creating Minimap2 indices by mapping to the compiled Human Genome hg38 
Method 
number 
Reference Parameters Description of action Description of results 
1 Compiled Human 
Genome hg38  
-k 1 (index)   -G 50000 
-d index file  --secondary=no 
Testing low k and low 
G 
Unsuccessful - did not produce 
output 
2 Compiled Human 
Genome hg38   
 
-k 1 (index)   -G 200000 
-d index file  --secondary=no 
Testing low k and 
moderate G 
Unsuccessful - did not produce 
output 
3 Compiled Human 
Genome hg38 
-k 1 (index)   -G 500000 
-d index file  --secondary=no  
 
Testing low k and 
high G 
Unsuccessful - did not produce 
output 
 
4 Compiled Human 
Genome hg38 
-k 14   -G 50000 
-d index file  --secondary=no 
Testing moderate k 
and low G 
Successful 
 
5 Compiled Human 
Genome hg38 
-k 14   -G 200000 
-d index file  --secondary=no  
 
Testing moderate k 
and moderate G 
Successful - produces similar 
output to 4 
 
6  Compiled Human 
Genome hg38  
-k 14   -G 500000 
-d index file  --secondary=no  
 
Testing moderate k 
and high G 
Successful - produces similar 
output to 4 
 
7 Compiled Human 
Genome hg38 
-k 28   -G 50000 
-d index file  --secondary=no  
 
Testing high k and 
low G 
Successful - produces similar 
output to 4 
 
8 Compiled Human 
Genome hg38   
-k 28   -G 200000 
-d index file --secondary=no  
 
Testing high k and 
moderate G 
Successful - produces similar 
output to 4 
 
9 Compiled Human 
Genome hg38   
-k 28 -G 500000 
-d index file  --secondary=no  
 
Testing high k and 
high G 
Successful - produces similar 
output to 4 
 
 




All Minimap2 indices were able to be successfully created using all the different types of references genomes. The index ‘k’ overrides 
the ‘k’ value set in the subsequent command for alignment, whereas this is not the case for the ‘G’ parameter. Therefore, only the ‘k’ 
parameter was set in indexing as opposed to using both ‘k’ and ‘G’ parameters (Table 3.2).  
 
 
Table 3. 2 List of tested methods for creating Minimap2 indices 
Index 
number 





Compiled Human Genome hg38  -k14 Making an index with 
the compiled Human 
Genome Reference 
Build hg38 setting k-
mer as 14 
Successful 
2 Human Genome hg38  -k14 Making an index with 
the Human Genome 
Reference Build hg38, 
setting k-mer as 14 
Successful 
3 Human Transcriptome -k14 Making an index with 
the Human 
Transcriptome, setting 
k-mer as 14  
Successful 
4 Gencode v28 annotation GFF3 file  -k14 Making an index with 
the Gencode v28 
aannotation file 
Successful 
5 Reference_genome_panel.fasta -k14 Making an index with 
fasta sequences of 
genes of interest 
Successful 
  




Minimap2 was used to align FASTQ files to various indices created in Table 3.2. The parameter ‘ax splice’ allowed splicing 
information to be considered, and the parameter ‘uf’ sets the transcript strand to find the GT-AG sites. ‘--secondary=no’ allowed only 
primary alignments to be included in the output data (H. Li, 2018a). Method number 2 produced the best alignment according to the 
output results on IGV (Table 3.3). 
 
Table 3. 3 List of tested parameters for aligning with Minimap2 
Method 
number 
Index Parameters Description of action Description of results 
1 1 -ax splice 
-uf 
 
Aligning FASTQ files to the 
index made via the compiled 
Human Genome Reference 
Build hg38 
Successful - can see mostly well-aligned reads on IGV 
2 2 -ax splice 
-uf 
Aligning FASTQ files to the 
index made via the compiled 
Human Genome Reference 
Build hg38 
Successful - similar but superior mapping compared to 1. 
3 3 -ax splice 
-uf 
Aligning FASTQ files to the 
index made via the Human 
Transcriptome 
 
Successful - however, difficult to visualise on IGV with 
gene names alone. Need transcript ID information 
4 4 -ax splice 
-uf 
Aligning FASTQ files to the 
index made via the Gencode 
v28 annotation GFF3 file 
Unsuccessful - Error seen on IGV 




Aligning FASTQ files to the 
index made via FASTA files of 
genes of interest 
Unsuccessful - Error: segmentation fault (core dumped) 
when the concatenated pass file was tried to be aligned  
 
 




FASTQ files were converted to FASTA files to be aligned with BLAT. The parameter ‘t’ is the database type, ‘q’ is the query type, 
‘stepSize’ is the spacing between tiles, ‘repMatch’ is the number of repetitions allowed before it is marked as overused. ‘minScore’ 
sets the minimum score, ‘minIdentity’ sets the minimum sequence identity. The parameter ‘out’ sets the type of output file and ‘fine’ 
allows the search for small initial and terminal exons (Kent, 2002). All three trials resulted in unsuccessful outcomes, with non-
interpretable outputs (Table 3.4).  
 
Table 3. 4 List of tested parameters for aligning with BLAT 
Method 
number 




-t=dna   -q=rna 
-stepSize=5  -repMatch=2253 
-minScore=0   -minIdentity=0 
-out=pslx   -fine 
Aligning FASTA files to 
the Human Genome hg38.  
Output file = PSLX 
Unsuccessful - Introns 
and exons could not 




-t=dna   -q=rna 
-stepSize=5   -repMatch=2253 
-minScore=0   -minIdentity=0 
-out=pslx   -fine 




Output file = PSLX 
Unsuccessful – Output 




-t=dna   -q=rna 
-stepSize=5   -repMatch=2253 
-minScore=0   -minIdentity=0 
-out=blast8   -fine 




Output file = BLAST8 
Unsuccessful - Output 
on IGV could not be 
interpreted 




Gmap_build was used to build the databases which were used as references for the alignment step (Table 3.5). The databases were 
used to align FASTA files converted from FASTQ files. The Uracil in these files were converted to Thymines using a GALAXY 
cDNA converter (Table 2.5) after the DRS FASTA files were unable to produce successful outcomes. The parameter ‘t’ sets the 
number of threads used, ‘f’ sets the output file type, ‘n’ sets the number of paths (T. Wu, 2018). All four trials of GMAP were 
unsuccessful, in which both the Human Genome Reference Build hg38 dataset and Human Transcriptome were used to align the reads 
(Tables 3.5-3.6).  
 
Table 3. 5 Comparison of parameters creating GMAP databases 
Database 
number 
Reference Parameters Description of action Description of results 
1 Human Transcriptome gmap_build 
-d name of database 
-D path to reference file 
Building a GMAP 
database with the Human 
Transcriptome 
Successful 
2 Human Genome hg38 gmap_build 
-d name of database 
-D path to reference file 
Building a GMAP 










Table 3. 6 List of tested parameters for aligning with GMAP 
Method number Database Parameters Description of action Description of results 




Aligning FASTA files to a 
database made with Human 
Genome hg38.  
Output = SAM file 
Unsuccessful -Error: genomic 
sequence is unusually long. 
Error: No paths found 
Processed 17 queries 




Aligning FASTA files to a 
database made with Human 
Transcriptome. 
Output = SAM file  
Unsuccessful -Error: No 
paths found 
Processed 17 queries 





Aligning FASTA files to a 
database made with Human 
Transcriptome. 
Output = GFF3 file  
Unsuccessful –Error:  
- gmap.avx2 does not exist 
-No paths found 
-Processed 173 reads from 
folder of over 200,000 reads 
 
4 2 -D output directory 





Aligning DRS FASTA files 
converted to cDNA to the 
gmap database created with the 
Human Transcriptome 
Unsuccessful -Produced a 











LAST was used to create a single database using the Human Genome Reference Build hg38 as the reference. The parameters 
implemented in Table 3.8 were used as they were pre-defined parameters set by the creators of LAST for long RNA sequencing. The 
parameter ‘P’ sets the number of processors, ‘uNEAR’ finds alignments with low rates of substitution, ‘d’ sets the minimum score for 
gapless alignments, ‘m’ sets the maximum initial matches per query position and ‘D’ sets query letters per random alignment (M. 
Frith, 2018). However, the default parameters for long RNA sequencing alignment produced unsuccessful results with the data from 
experiment 1 (Tables 3.7-3.8) 
 
 
Table 3. 7 Comparison of parameters creating LAST databases 
Database 
number 








Name of database 
Path to reference FASTA file 
Making a database with default 
parameters for long nanopore 
reads 
Successful 




Table 3. 8 List of tested parameters for aligning with LAST 
Method 
number 
Database Parameters Description of action Description of results 
1 1 Parallel-fasta 
Lastal 












Aligning FASTA files to the 
database made with Human 
Genome hg38.  
Unsuccessful - produced count 
text file with no content and a 
par file with lack of 
information 
 




3.3.2 Summary of alignment  
Minimap2 provided the best alignment and parameter combination among the four aligners 
tested, and therefore the rest of the analyses were carried out using Minimap2 with the suggested 
ONT DRS parameters. Minimap2 was used to align the reads to the Human Genome or the 
Human Transcriptome (Table 2.4). The results obtained from alignment were compared to an 
external dataset from the Nanopore RNA Consortium (Table 2.4). 
 
3.3.3. Visual output of sequenced reads 
The resulting BAM files from the alignment step were visualised on IGV as shown in Fig. 3.2-
3.9. IGV screenshots of mRNA alignments to the Human Genome are shown in Fig. 3.2, 3.4, 3.6 
& 3.8. IGV screenshots of mRNA alignments to the Human Transcriptome are shown in Fig. 
3.3, 3.5, 3.7 & 3.9. Alignments of DRS reads for several genes of interest were illustrated, 
including the hereditary breast and ovarian cancer genes (BRCA1, CHEK2 and RAD51C) and a 
housekeeping gene (GAPDH). The output of the sequenced reads revealed a 3’ bias for most 
genes. High levels of control genes, such as GAPDH (Figures 3.6-3.7), and very low expression 
of genes of interest, such as BRCA1 were observed (Figures 3.2-3.3). Some reads were 
ambiguous in alignment, with very short fragments aligned in the middle of the gene as opposed 
to the 5’ or 3’ ends. For example, BRCA1 showed 12 reads spanning only exon 14, compared to 
only 11 reads being present at the 3’ end (Figure 3.2). These ambiguous alignments were more 
common in genes with lower expression level and longer transcript length, such as BRCA1. 
Furthermore, full-length isoforms were more common in genes with high expression levels and 
shorter transcript lengths, such as GAPDH and RAD51C (Table 3.6). 





The output shows the scarcity of BRCA1 transcripts within the isolated mRNA sample and a 3’ bias. First 23 reads of BRCA1 transcripts are 
illustrated with high rates of indels, which are characteristic of nanopore sequencing data. Gene structure is shown at the bottom of the track, with 
exons shown as blue blocks and introns represented as blue horizontal lines. Transcription direction is from right to left. The reference genome, 
chromosome location and coordinates are shown at the top left corner. Coverage is shown by the density and height of vertical lines above the 
transcripts.  
Figure 3. 2 IGV screenshot showing BRCA1 RNA transcripts from experiment 1, aligned to the Human Genome via Minimap2. 





The output shows the scarcity of BRCA1 transcripts within the isolated mRNA sample and a 3’ bias. First 10 reads of BRCA1 transcripts are 
illustrated, with high rates of indels, which are characteristic of nanopore sequencing data. The reference transcriptome and transcript type are 
shown in the top left corner. Coverage is shown by the density and height of vertical lines above the transcripts.  
Figure 3. 3 IGV showing BRCA1 RNA transcripts from experiment 1, aligned to the Human Transcriptome via Minimap2. 





The output shows the scarcity of CHEK2 transcripts within the isolated mRNA sample, and a 3’ bias. First 11 reads of CHEK2 transcripts are 
illustrated with high rates of indels, which are characteristic of nanopore sequencing data. Gene structure is shown at the bottom of the track, with 
exons shown as blue blocks and introns represented as blue horizontal lines. Transcription direction is from right to left. The reference genome, 
chromosome location and coordinates are shown at the top left corner. Coverage is shown by the density and height of vertical lines above the 
transcripts.  
Figure 3. 4 IGV showing CHEK2 RNA transcripts from experiment 1, aligned to the Human Genome via Minimap2. 





The output shows the scarcity of CHEK2 transcripts within the isolated mRNA sample and a 3’ bias. First 9 reads of CHEK2 transcripts are 
illustrated, with high rates of indels, which are characteristic of nanopore sequencing data. The reference transcriptome and transcript type are 
shown in the top left corner. Coverage is shown by the density and height of vertical lines above the transcripts. 
Figure 3. 5 IGV showing CHEK2 RNA transcripts from experiment 1, aligned to the Human Transcriptome via Minimap2. 





The output shows the abundance of GAPDH transcripts within the isolated mRNA sample. First 38 reads of GAPDH transcripts are illustrated 
with high rates of indels, which are characteristic of nanopore sequencing data. Gene structure is shown at the bottom of the track, with exons 
shown as blue blocks and introns represented as blue horizontal lines. Transcription direction is from left to right. The reference genome, 
chromosome location and coordinates are shown at the top left corner. Coverage is shown by the density and height of vertical lines above the 
transcripts.  
Figure 3. 6 IGV screenshot showing GAPDH RNA transcripts from experiment 1, aligned to the Human Genome via Minimap2. 




The output shows the abundance of GAPDH transcripts within the isolated mRNA sample. First 43 reads of GAPDH transcripts are illustrated, 
with high rates of indels, which are characteristic of nanopore sequencing data. The reference transcriptome and transcript type are shown in the 
top left corner. Coverage is shown by the density and height of vertical lines above the transcripts.  
Figure 3. 7 IGV showing GAPDH RNA transcripts from experiment 1, aligned to the Human Transcriptome via Minimap2. 





The output shows the abundance of RAD51C transcripts within the isolated mRNA sample. First 16 reads of RAD51C transcripts are illustrated 
with high rates of indels, which are characteristic of nanopore sequencing data. Gene structure is shown at the bottom of the track, with exons 
shown as blue blocks and introns represented as blue horizontal lines. Transcription direction is from left to right. The reference genome, 
chromosome location and coordinates are shown at the top left corner. Coverage is shown by the density and height of vertical lines above the 
transcripts.  
Figure 3. 8 IGV showing RAD51C RNA transcripts from experiment 1, aligned to the Human Genome via Minimap2. 






The output shows the abundance of RAD51C transcripts within the isolated mRNA sample. First 11 reads of RAD51C transcripts are illustrated, 
with high rates of indels, which are characteristic of nanopore sequencing data. The reference transcriptome and transcript type are shown in the 
top left corner. Coverage is shown by the density and height of vertical lines above the transcripts.  
Figure 3. 9 IGV showing RAD51C RNA transcripts from experiment 1, aligned to the human transcriptome via Minimap2. 




3.3.4 Quantification of MinION-generated reads 
Different quantification software was trialled by testing different parameters, and the results are 
shown below (Tables 3.9-3.14). All quantification programmes were unable to quantify the 
aligned reads with the parameters outlined in Tables 3.9-3.14.




The Kallisto programme was used to create indices based on the Human Genome Reference Build hg38 and the Human 
Transcriptome (Table 2.4). The parameter ‘single’ allows quantification of single-end reads, ‘l’ sets the estimated average fragment 
length, ‘s’ sets the estimated standard deviation of the fragment length, and ‘t’ sets the number of threads (Pachter, 2016). The 




Table 3. 9 Comparison of parameters creating Kallisto indices 
Method 
number 




-i index file name 






-i index file name 











Table 3. 10 List of tested parameters for DRS quantification using Kallisto 
Method number Index Parameters Description of action Description of results 
1 1 --single 
-l 738 
-s 384 
-t 4  
Quantifying the 
transcripts from MinION 
run aligned to the Human 
Genome hg38 
Unsuccessful – produced no count data 
2 2 --single 
-l 738 
-s 384 
-t 12  
Quantifying the 
transcripts from MinION 
run aligned to the Human 
Transcriptome 














Salmon indices were created with only the Human Transcriptome, as this was the default reference for Salmon. Both alignment and 
non-alignment modes were trialled. The parameter ‘l’ sets the library type, ‘p’ sets the number of threads, ‘fldMean’ sets the expected 
mean fragment length, ‘fldSD’ sets the expected standard deviation, ‘validateMappings’ runs an extension alignment dynamic on the 
quasi-mapppings and ‘rangeFactorizationBins’ is a parameter that may allow improved quantification estimates. The parameter 
‘gcbias’ allows correction for GC bias in the data, ‘writeUnmappedNames’ makes Salmon write out the names of unmapped reads, 
and ‘minAssignedFrags’ sets the minimum number of assigned fragments (R. Patro, G.  Duggal, M. I. Love, R. A. Irizarry, & C.  
Kingsford, 2017) (Tables 3.11-3.12). Alignment-based mode with sorted BAM files of Minimap2 aligned reads were able to generate 
count data, which were non-integer values. Therefore, Salmon was unable to successfully quantify the reads.  
 
 
Table 3. 11 Parameters for creating Salmon indices 
Method 
number 




-t reference genome 
--type quasi 
-k 31 
Building a Salmon index with the 
Human Transcriptome in quasi-index 








Table 3. 12 List of tested parameters for DRS quantification using Salmon 
Method 
number 
Index Parameters Description of action Description of results 
1 1 quant   
-l A  -p 4 
--fldMean 738    --fldSD 384 
--validateMappings  --rangeFactorizationBins 4 
--gcBias   --writeUnmappedNames u  
 
Quantifying the transcripts from MinION 
run aligned to the Human Genome hg38 
with an index created from the Human 
Transcriptome in quasi-index mode 
Unsuccessful 
2 1 quant 
-l A  -p 4 
--fldMean 73  --fldSD 384 
--validateMappings   --rangeFactorizationBins 4 
--writeUnmappedNames   --minAssignedFrags 1 
Quantifying the transcripts from MinION 
run aligned to the Human Genome hg38 
with an index created from the Human 
Transcriptome in quasi-index mode  
Unsuccessful 
3 1 quant 
-l A 
 
Quantifying the transcripts from MinION 
run aligned to the Human Genome hg38 
with an index created from the Human 
Transcriptome in quasi-index mode  
Unsuccessful 
4 1 quant 
-l A 
Quantifying the transcripts from MinION 
run aligned to the Human Transcriptome 
with an index created from the Human 









(sorted BAM file) 
Quantifying the transcripts from MinION 
run aligned to the Human Transcriptome 
in alignment-based mode with a sorted 
BAM file 
Unsuccessful – produces 
count data with integer 
values which do not 
correspond to the output 
on IGV 
6 None quant 
-l A 
(unsorted bam file) 
Quantifying the transcripts from MinION 
run aligned to the Human Transcriptome 
in alignment-based mode with an unsorted 
BAM file 
Unsuccessful – produces 
non-integer count data 
 
 




Mandalorion – Episode II was used in order to quantify the isoforms aligned by Minimap2. The parameter ‘u’ defines how lenient 
TSS and polyA sites are defined upstream, ‘d’ defines how lenient TSS and polyA sites are defined downstream, ‘s’ defines how 
many randomly sampled subreads are used to create an isoform consensus, ‘r’ determines the minimum ratio of reads aligned to a 
locus, ‘R’ sets the minimum number of reads that have to be assigned to an isoform for the isoform to be reported, ‘I’ sets the 
maximum 5’ overhang, ‘i’ sets the minimum 5’ overhang, ‘T’ sets the maximum 3’ overhang, and ‘t’ sets the minimum 3’ overhang 
(R.  Volden & Vollmers, 2018) (Table 3.13). 
Table 3. 13 List of tested parameters for DRS quantification using Mandalorion – Episode II 
Method number Reference Parameters Description of action Description of results 




-c content file 
-p output directory 
-u 5  -d 30  -s 200  -r 0.05 
-R 1  -I 0  -t 0  -I 100  -T 60 
-g path to Mandalorion 
NUC.4.4.mat file 




Quantifying the transcripts 
from MinION run aligned 
to the Human 
Transcriptome and 
referenced to the Gencode 
v28 annotation GTF file 
with the 
defineAndQuantifyIsoform
s.py python script.  
Unsuccessful- Error: 
ValueError: invalid literal 
for int() with base 10 




-c content file 
-p output directory 
-u 5  -d 30  -s 200  -r 0.05 
-R 1  -I 0  -t 0  -I 100  -T 60 
-g path to Mandalorion 
NUC.4.4.mat file 
Path to annotation GTF file 
-m config_file 
Quantifying the transcripts 
from MinION run aligned 
to the Human 
Transcriptome and 
referenced to the Gencode 
v28 annotation GTF file 
with the 
defineAndQuantifyWrappe
r.py python script.  
Unsuccessful -Error: 
UnicodeDecodeError:  
‘utf-8’ codec can’t 
decode bytes in position 
15-16: invalid 
continuation byte 




SQANTI utilised GMAP databases (Table 3.5) and was used to quantify reads in a FASTA format. The parameter ‘n’ allows the gene 
name tag from the annotated GTF file to be used to define the gene and the parameter ‘t’ sets the number of GMAP threads (de la 
Fuente & Tardaguila, 2018) (Table 3.14). Various errors were produced through these steps, therefore, quantification using these 



























-x path to gmap database    -t 4 
-o name of output file 
-d path to output directory 
Query FASTA file 
Annotation GTF file  
Reference FASTA file 
 
Quantifying the transcripts from MinION 
run aligned to the Human Transcriptome 
Unsuccessful: 
-Many no paths found 
errors 






-x path to gmap database  -t 4 
-o name of output file 
-d path to output directory 
Query FASTA file 
Annotation GTF file  
Reference FASTA file 
 
Quantifying the transcripts from MinION 
run aligned to the Human Genome (Used 
the cDNA FASTA) 
Unsuccessful 
-Many no paths found 
errors 
-OSError: [Errno 13] 
Permission denied 
3 1 Python 
Path to Sqanti_qc.py 
Query FASTA file 
Annotation GTF file 
Reference FASTA file 
-n   -t 4 
-x path to gmap database 
Quantifying the transcripts from MinION 
run aligned to the Human Transcriptome 
(Used the cDNA FASTA) 
Unsuccessful – 
IndexError: list index 
out of range 
 






The results of this chapter revealed that a successful first DRS run had been carried out in this 
laboratory by visualising the reads on IGV (Figures 3.2-3.9). Satisfactory quality mRNA was 
isolated and sequenced with the MinION via the Direct RNA Sequencing Kit. The results 
showed that the MinION had successfully sequenced full-length isoforms of many genes 
including GAPDH and RAD51C. However, full-length transcripts of many poorly expressed 
genes, such as BRCA1, were not well represented using a whole transcriptome DRS approach 
(Figure 3.2). Only four genes of interest have been described in this chapter, however, many 
other genes were also sequenced as a part of this whole transcriptome sequencing experiment. 
The data generated from this experiment was used as a control experiment for subsequent 
enrichment experiments outlined in chapter 4.  
 
 
3.4.2 Basic data acquisition  
Data acquisition with MinKNOW and Albacore was straightforward, as the software was 
provided by ONT. Basecalling with Albacore produced ‘pass’ and ‘fail’ reads, in which the 
number of ‘pass’ reads were greater than ‘fail’ reads in this experiment. This suggests that most 
of the reads were of satisfactory quality to be sequenced with the MinION.  
 





The results showed positive alignment with the use of Minimap2. However, BLAT, GMAP and 
LAST did not produce successful alignments. These four aligners were tested as they have been 
previously used with nanopore data (Croville et al., 2018; de Jong et al., 2017; Ip et al., 2015). 
Minimap2 indices were successfully created with moderate to high k-mers, whereas low k-mers 
were unable to produce an index. K-mers are all the possible subsequences that may be generated 
from a string of length k (Marcais & Kingsford, 2011). Therefore, using a k-mer length of 1 may 
have caused this unsuccessful result (Table 3.1). Genome alignment was preferred over 
transcriptome alignment as it provided exon-intron information, which was beneficial for 
detecting exon-skipping events on IGV. The compiled Human Genome hg38 (Table 2.4) by Dr 
Heng Li was used initially as it was believed that the standard Human Genome Reference Build 
hg38 was inadequate for alignment, with properties such as the exclusion of unplaced and 
unlocalised contigs (H. Li, 2017). However, upon closer examination, the alignment of BRCA1 
was similar or slightly improved compared to the standard Human Genome Reference Build 
hg38 (Table 2.4). Therefore, the rest of the analyses were carried out with the standard genome.  
 
Minimap2 has defined parameters specific for ONT DRS data, whereas BLAT lacked this 
information. BLAT produced PSLX and BLAST8 files (Table 3.4), and the PSLX files were 
converted to SAM files via the script psl2sam.py. The resulting SAM file was converted to 
BAM, sorted, and indexed with Samtools. On IGV, the sorted BAM file was incomprehensible, 
showing unidentifiable reads with lack of exon-intron information even with aligning to the 
Human Genome instead of the Human Transcriptome. BLAT uses a client/server mode, and its 
cDNA genomic alignments are known to be ambiguous (T. D. Wu & Watanabe, 2005). 




Alignment to the BRCARD1_geneseq.fasta file (Table 2.4) also followed these results. One 
reason which may have caused these results may be due to DRS reads being aligned instead of 
converted cDNA sequences.   
 
In contrast, GMAP is beneficial for obtaining isoform information, however, it proved to be 
more laborious than Minimap2 for processing ONT DRS reads. As GMAP only processes cDNA 
reads, the DRS were converted to cDNA sequences and aligned to a transcriptome. All alignment 
trials presented with a ‘no paths found’ error (Tables 3.5-3.6), which may be due to the low 
quality of the reads. GMAP involves a single query/interactive mode instead of a client/server 
mode. This allows higher processing speed for individual queries, as GMAP searches for 
oligomers directly from the file instead of accessing the data from a server (T. D. Wu & 
Watanabe, 2005). 
 
A LAST database was created successfully (Table 3.7), however, the given parameters for long 
DRS reads were unable to align the data generated from experiment 1 (Table 3.8). Therefore, 
this may suggest that the reads generated from the DRS experiment or the trialled parameters 
were suboptimal. The parameters for minimum score for gapless alignment, maximum initial 
matches per query position and query letters per random alignment should be tested in future 
experiments to optimise this alignment.  
 
The bioinformatic errors observed in these experiments (Tables 3.4-3.6 & 3.8) were unable to be 
overcome due to time constraints. For these collective reasons, Minimap2 was used as the aligner 




for the final pipeline and was utilised for aligning all subsequent DRS data and the external 
Nanopore RNA Consortium dataset (Table 2.4).  
 
 
3.4.4 Quantification of reads 
Quantification programmes also proved to be problematic (Tables 3.9-3.14), with all tested 
programmes failing to quantify reads aligned with various reference genomes (Table 2.4). 
Kallisto was unable to produce count data, whereas Salmon was able to produce count data 
including TPM and number of reads by using the Transcriptome as the reference genome. 
However, the output of Salmon did not correlate with the reads visualised on IGV. Therefore, it 
appeared that Salmon was unable to accurately quantify reads from long DRS reads. This result  
may have occurred because these programmes have been designed for short or long RNA-seq 
reads, as opposed to DRS reads. Even with the reads being converted to cDNA sequences, the 
quantification programmes failed to count isoforms. 
 
Mandalorion – Episode II (Table 3.13) and SQANTI (Table 3.14) have been designed for long 
nanopore and PacBio reads, respectively. Mandalorian – Episode II is specific for Rolling Circle 
Amplification to Concatemeric Consensus (R2C2) (R. Volden et al., 2018), and is not specific 
for DRS. Similarly, SQANTI has been designed for long-read RNA-seq and was suggested as a 
putative quantifier for long DRS reads. However, none of the attempted experiments were able to 
produce a successful outcome (Table 3.14).   




Therefore, reads were manually counted by visualising them on IGV, and recording the data in 
an Excel spreadsheet. Each gene of interest was designated for a particular type of reference 
transcript variant to standardise the exon numbering across the datasets (BRCA1 – NM_007294, 
CHEK2 – NM_001257387, GAPDH – NM_001289745, RAD51C – NM_058216). During this 
process, human error may have been introduced, which means that the outputs of these analyses 
may be inaccurate. However, some inferences can be cautiously made with these data, as in the 
upcoming chapters.  
 
 
3.4.5 Comparison with the Nanopore RNA Consortium dataset 
As replicated experiments were not carried out, the data from experiment 1 was supplemented 
with an external dataset from the Nanopore RNA Consortium (Table 2.4). The consortium data 
involved 30 flow-cells which generated approximately 13 million DRS reads, whereas the results 
from experiment 1 involved 1 flow-cell, which sequenced 889,850 reads. Therefore, the 
throughput of this experiment 1 was satisfactory. The Nanopore RNA Consortium data 
implemented poly-A RNA instead of total RNA as in experiment 1. However, the consortium 
data used a control LCL (NA 12878) without NMD inhibition, whereas experiment 1 utilised a 
different control LCL (Table 2.1) with NMD inhibition. The specific comparisons between 
different experiments and external datasets will be outlined in subsequent chapters. In chapter 4, 
a novel method for enriching targeted transcripts will be explored. 




Chapter 4: Developing a gene enrichment method for 
targeted direct RNA sequencing 
 
4.1 Introduction 
The purpose of these experiments was to test a novel linear enrichment method to amplify RNA 
isoforms of interest, in order to provide an improved method of examining the effects of VUS on 
splicing patterns. A brief overview of the sequence of steps involved in these experiments are 
outlined in Figure 3.1 and Figure 4.1. In experiment 2, GAPDH was utilised as a control gene 
and was also enriched and sequenced along with BRCA1. In experiment 3, BRCA1 and 11 other 
hereditary breast and ovarian cancer genes with a range of different transcript lengths and 
expression levels were utilised to test the enrichment with this novel enrichment technique 
(Table 1.1). Because this multi-gene approach did not prove to be very successful, experiment 4 
was a more modest approach to enrichment of four genes, GAPDH (housekeeping gene), 
BRCA1, CHEK2 and RAD51C (hereditary breast and ovarian cancer genes). GAPDH, CHEK2 
and RAD51C have similar transcript lengths (1.2 KB-1.9 KB) (Table 4.1), but different 
expression levels. Experiment 1 data, external RNA-seq data and external DRS data (Table 2.4) 
were implemented to compare the results of these experiments.




Table 4. 1 List of genes of interest implemented in this study and their characteristics 
Gene Gene Length Transcript Length Expression Level 
BRCA1 81 KB 7.2 KB Low  
BRCA2 84 KB  11 KB Moderate 
PALB2 38.1 KB 4.7 KB High 
RAD51B 863 KB 3.3 KB Very high 
RAD51C 42.2 KB 1.2 KB High 
RAD51D 20 KB 2.5 KB High 
BRIP1 185 KB 6.4 KB Moderate 
BARD1 84 KB  4 KB Moderate 
ATM 147 KB 10 KB Low 
CHEK2 54.1 KB 1.9 KB Moderate 
FANCM 64.9 KB 6.4 KB Low 
NBN 51.4 KB 4.6 KB High 





*The transcript lengths were inferred from Geneious (version 11.1.4) and the expression level was inferred from an external RNA-seq dataset 
(Table 2.4).






The mRNA from the extracted total RNA was reverse-transcribed into an RNA-cDNA hybrid using an 
anchored oligo-dT(20) primer. An RNAse was implemented to digest the RNA strand, whereas the cDNA 
remained intact. A second cDNA strand was synthesised in order to incorporate a T7 polymerase binding 
site attached to a gene specific primer. The double-stranded cDNA was isolated by HighPrep™ magnetic 
beads. The T7 RNA polymerase was utilised to generate in vitro transcribed RNA. This RNA was 
isolated by RNAClean™ XP magnetic beads and used to generate a MinION library. The library was 
loaded on a flow-cell and sequenced with the MinION.  
Figure 4. 1 A brief schematic of the enrichment approach. 




4.2 RNA source/cell culturing 
More control LCL (Table 2.1) batches were grown to carry out experiments 2-4 with the same 
aforementioned conditions. From these cultures, another 15 RNA extractions were carried out 
via the RNeasy® Mini Kit. The extracted total RNA had satisfactory quality, determined from 
NanoDrop™, Qubit™ RNA HS and Tapestation assays. Tapestation results were consistently 
above a RINe score of 9.3. However, NanoDrop™ and Qubit™ results varied between all 15 
RNA samples. The average NanoDrop™ concentration was 878.21 ng/µL and the average 
Qubit™ RNA HS result was 585.85 ng/µL.  
  
4.3 First cDNA strand synthesis   
The first strand of cDNA was reverse-transcribed from total RNA extracted from a control LCL 
using the enzyme Superscript® III Reverse Transcriptase according to Appendix C. Here, an 
anchored oligo-dT(20) primer was utilised. The RNA strand was degraded by the use of an 
RNAse enzyme (Table 2.1), in which the cDNA strand was left single-stranded (Figure 4.1). 
Quality of the cDNA from this step was examined by a series of different quality control 










4.3.1 Standard long-range PCR  
Thirteen standard long-range PCR reactions were carried out to determine the efficacy of the first 
cDNA strand synthesis step. BRCA1 exon 1 forward and exon 24p reverse primers were utilised 
to visalise any full-length BRCA1 cDNA present in the single-stranded cDNA sample. The 
results shown on one gel revealed prominent bands of approximately 2.4 KB (Figure 4.2 A), and 
the results from the second gel revealed a bright, prominent band of approximately 2.4 KB and 
thinner bands around 6 KB and 2.2 KB (Figure 4.2 B). The 6 KB band represented full-length 
isoforms of BRCA1. However, the rest of the PCRs had failed, with smears observed as opposed 
to distinct bands. Therefore, the alternative long-range PCR was explored.   
 
 




A)                                                                                     B)  
 
BRCA1 exon 1 forward and exon 24p reverse primers were used in the PCR. A) Thick bands around the 
size of 2.4 KB were shown. B) A thick band around 2.4 KB, along with two thinner bands around 2.2 KB 






Full-length BRCA1 isoform 
Figure 4. 2 Agarose electrophoresis gels of standard long-range PCR products. 




4.3.2 Alternative long-range PCR 
An alternative long-range PCR (Figure 4.3) was carried out to determine the efficacy of the first 
strand cDNA synthesis step, as a substitute for the standard long-range PCR. This PCR consisted 
of a higher MgCl2 and cDNA concentration, lower dNTP concentration and lower initial 
denaturation and extension times compared to the standard long-range PCR (Figure 4.2). BRCA1 
exon 1 forward and exon 24p reverse primers were utilised to visalise whether any full-length 
BRCA1 cDNA was present in the single-stranded cDNA sample. The gel produced two bright 
and prominent bands of approximately 5.8 and 2.8 KB sizes, which presented improved bands 













The gels were set at 1% at 90 V for 30 minutes – 1 hour. BRCA1 exon 1 forward and exon 24p reverse 
primers were used in the PCR. The gel showed presence of bright and prominent bands of approximately 
5.8 KB and 2.8 KB sizes.  
Figure 4. 3 Agarose electrophoresis gel of alternative long-range PCR products. 




4.4 Second cDNA strand synthesis  
In experiment 2, GAPDH and BRCA1 T7-GSP forward primers were added separately into two 
different reaction volumes for the targeted enrichment of GAPDH and BRCA1. In experiment 3, 
12 T7-GSP forward primers were pooled and mixed, and an aliquot of 5 µM were used in one 
reaction volume (Table 2.2). In experiment 4, four reaction volumes were carried through the 
second strand cDNA synthesis step, one for each gene of interest; GAPDH, BRCA1, RAD51C, 
CHEK2. Different cycling conditions were used in experiment 4 to the other experiments.  
Experiments 2 and 3 used 1 cycle of 94 °C for 1 minute, 50 °C for 1 minute and 65 °C for 30 
minutes. Experiment 4 used 3 cycles of 94 °C for 1 minute, 50 °C for 1 minute and 65 °C for 30 
seconds. The product was then placed into a refrigerator for 10 minutes, and an extra step of 65 
°C for 30 minutes were exerted on the dscDNA product.  




4.4.1 Temperature gradient PCR 
The temperature gradient PCR was used to determine the optimum annealing temperature for the 
second cDNA strand synthesis step. The manufacturer recommends an annealing temperature 
ranging from 45 to 65 °C for the second cDNA synthesis step 
(https://international.neb.com/protocols/2012/10/15/m0323-longamp-taq-dna-polymerase-
protocol). However, as each melting temperature (Tm) of a primer was different to other primers 
(Table 2.2), the optimum annealing temperature was speculated to be also different for each 
primer. Hence, a temperature gradient PCR was carried out to determine the optimum annealing 
temperature for the T7-GSP primer for BRCA1 and GAPDH. BRCA1_F1 and BRCA1_7R 
primers were used for BRCA1, and GAPDH_F1 and GAPDH_R9 primers were used for 
GAPDH. The results of the temperature gradient PCR showed that temperatures from 49.8 °C to 
62.0 °C proved to be optimum annealing temperatures for the second cDNA synthesis for 
BRCA1 (Figure 4.4). In comparison, temperatures from 49.8 °C to 65.1 °C were found to be 
optimum annealing temperatures for GAPDH (Figure 4.5). Therefore, 50 °C was used as the 
annealing temperature for the second cDNA strand synthesis for all enrichment experiments. 
Furthermore, expected band sizes of 900 bps and 1.2 KB were found for BRCA1 (Figure 4.4) 























BRCA1 exon 1 forward and exon 7 reverse primers were used in the PCR. Products with annealing 
temperatures from 49.8 °C to 62.0 °C produced prominent fragments of around 900 bps. With increasing 
temperatures above 62 oC, the quantity of product tailed off markedly. The gels were set at 1 % at 90 V 









Figure 4. 4 Agarose electrophoresis gel of BRCA1 temperature gradient PCR products. 


















GAPDH exon 1 forward and exon 9 reverse primers were used in the PCR. Products with annealing 
temperatures from 49.8 °C to 65.1 °C produced prominent fragments of around 1.2 KB.  The gels were 








Figure 4. 5 Agarose electrophoresis gel of GAPDH temperature gradient PCR products. 




4.4.2 T7-Only Primer PCR 
A T7-only primer PCR was utilised for testing the efficacy of the second cDNA strand synthesis. 
The T7-GSP primer was used as a means of providing a binding site for the T7 RNA 
polymerase, with a gene specific primer attached to target the gene of interest. This was 
necessary for the in vitro transcription step which followed the second cDNA strand synthesis 
step (Figure 4.1). A forward primer composed only of a T7-polymerase binding site, and a 
reverse primer close to the 5’ end of the second cDNA strand were implemented to test for 
incorporation of the T7-polymerase binding site into the second cDNA strand (Figure 4.6). The 
resulting gel revealed a band around 810 bps (Figure 4.7), which is the approximate length of 
exon 1 to exon 7 on BRCA1. This provides evidence that the T7 polymerase binding site had 
been successfully incorporated in the double-stranded cDNA.  
 
 
The forward primer was the T7-only primer and the reverse primer was an exon 7 reverse for BRCA1. 
This PCR determined whether the T7-GSP had been successfully incorporated into the second cDNA 
strand.   
 
Figure 4. 6 Diagram of a T7-only PCR. 














Figure 4. 7 Agarose electrophoresis gel of BRCA1 T7-only forward and exon 7 reverse primer PCR. 




4.4.3 T7-only & oligo-dT(20) (full-length) PCR 
T7-only and oligo-dT(20) primers were used as forward and reverse primers for this PCR, 
respectively (Figure 4.8). This was carried out in order to determine whether the second cDNA 
synthesis step had been carried out in a satisfactory manner in experiment 4 to produce dscDNA 
which spanned the whole length of the gene of interest. The products of four genes of interest 
(BRCA1, CHEK2, GAPDH, RAD51C) were tested. Ideally, the second cDNA strand should 
overlap the oligo-dT(20) to allow the in vitro transcribed RNA to contain a poly-A tail, which is 
crucial for the sequencing step (Figure 4.1). The gels showed varied results between different 
genes of interest (Figure 4.9). Genes with relatively high expression levels (GAPDH and 
RAD51C) presented bright, thick bands of approximately 1.5 KB and 1.2 KB, respectively. The 
genes with relatively low expression (BRCA1 and CHEK2) presented multiple thin, faint bands 
across a smear.  
 
 
The T7 RNA polymerase binding site primer was utilised as the forward primer, and the anchored oligo-
dT(20) primer was used as a reverse primer in these experiments. This PCR determines whether the second 
cDNA strand synthesis had been able to be completed to the 5’ end of the first cDNA strand.  
Figure 4. 8 Diagram of a T7-only & oligo-dT(20) PCR. 





The products of GAPDH, BRCA1, RAD51C, CHEK2. GAPDH and RAD51C presented bright, thick bands 
with sizes of 1.5 KB and 1.1 KB respectively. All four genes of interest showed smears across the length 
of the ladder, and thin, distinct bands were shown for BRCA1, RAD51C and CHEK2 samples above 2 KB. 







Figure 4. 9 Agarose electrophoresis gel of T7-only forward and anchored oligo-dT(20) reverse primer PCR. 




4.5 HighPrep™ magnetic bead clean-up 
The double-stranded cDNA produced with the T7-GSP primer was isolated by a HighPrep™ 
magnetic bead clean-up step. The double-stranded cDNA was eluted in 20 µL to concentrate the 
sample for use in the in vitro transcription step. The elution was analysed through the Qubit™ 
dsDNA HS Assay. In experiment 2, the result showed a concentration of 1.97 ng/µL for BRCA1 
products, and 1.96 ng/µL for GAPDH products. In experiment 3, the concentration was 16.6 
ng/µL. In contrast, experiment 4 showed concentrations of 12.6 ng/µL for GAPDH products, 
11.9 ng/µL for BRCA1 products, 10.6 ng/µL for CHEK2 products and 9.16 ng/µL for RAD51C 
products.  
 
4.6 In vitro transcription 
In experiment 2, the double stranded cDNA products were in vitro transcribed with the 
MEGAscript™ kit with 4 hours of incubation at 37 °C. Incubation times were 16 hours for 
experiment 3, and 20 hours for experiment 4. The Tapestation assay results were unable to be 
reported as the lower marker could not be detected by the reagents. Therefore, the quality of the 
in vitro RNA was not able to be determined.  
 
4.7 MinION library preparation 
The in vitro transcribed RNA from the previous step was used for the MinION library 
preparation step (Figures 2.1, 3.1, 4.1). The results of the RNAClean™ XP bead system in the 
DRS kit protocol of each experiment was measured by the Qubit™ RNA and dsDNA HS 




Assays. The RNA concentrations of experiments 2-4 were 54.4 ng/µL, 38 ng/µL, and 110 ng/µL 
respectively. The dsDNA concentrations of experiments 2-4 were 8.9 ng/µL, 2.56 ng/µL and 




4.8 MinION sequencing results  
The ONT DRS kit was used according to the protocol described in Appendix H. The isolated in 
vitro mRNA was reverse transcribed as a part of the protocol, and adapters were ligated to the 
mRNA (Figures 2.1, 3.1, 4.1). The sequencing was carried out for 48 hours and the sequenced 
reads were acquired by MinKNOW v1.14.1. Experiment 2, 3 and 4 generated total FAST5 files 
which were vastly different (Table 4.2). Albacore v2.3.0 was used to basecall these reads and 
generate FASTQ files. This produced ‘pass’ and ‘fail’ folders, for each experiment (Table 4.2).  
 
  
Table 4. 2 Results from basic data acquisition using MinKNOW and Albacore programmes 
Counts Experiment 2 Experiment 3 Experiment 4 
Total FAST5 460,846 45,584 1,147,161 
 
Pass reads from 
basecalling 
288,100 11,494 651,277 
Fail reads from 
basecalling 
170,435 32,868 383,808 
 





Alignment was successfully carried out with Minimap2 by aligning the reads to the Human 
Genome hg38. The visualisation on IGV showed that in most datasets, 3’ bias was present 
(Figures 4.11-4.13). Furthermore, the use of the Minimap2 generated superior alignment 
compared to other aligners.  
 
4.8.2 Quantification 
Each transcript isoform was counted and categorised manually by visualising the sorted BAM 
files on IGV. The counts of each isoform were based on one type of transcript – NM_007294 for 
BRCA1, NM_001257387 for CHEK2, NM_058216 for RAD51C and NM_001289743 for 
GAPDH. These genes formed a part of the 4th experiment, and as this experiment produced the 
best enrichment, only these genes were quantified to compare across experiments. Therefore, 
TPM values of these genes were calculated by multiplying the number of reads for each isoform 
with a factor consistent with each experiment (1,000,000/number of pass reads). Counts from 
experiment 3 were omitted for further analysis as insufficient reads were observed.  
 
External data from an international Nanopore RNA Consortium was used to compare the results 
from these experiments (Table 2.4). The total and subset (Notts_Run1) datasets included 
10,302,647 and 363,756 reads respectively, and were aligned, sorted, and indexed via parameters 
used in experiments 1-4. The sorted BAM file was visualised on IGV and transcript isoforms 
were counted manually for genes of interest (BRCA1, CHEK2, GAPDH and RAD51C). 




4.8.2.1 BRCA1 transcripts 
Enrichment for BRCA1 was evident in experiment 4 compared to the experiment 1 (control 
experiment) (Table 4.3). However, the coverage across all types of isoforms was lacking in 
depth, where most of BRCA1 transcripts from experiment 4 appeared to have a 5’ bias, starting 
from exon 1. In comparison, experiment 1 had a clear 3’ bias (Table 4.3). Furthermore, 
experiment 4 generated longer isoforms compared to experiment 1. Between the enrichment 
experiments, experiment 2 results presented the widest variety of isoform types compared to 
experiment 4, possibly due to utilising only one cycle of PCR during the second cDNA synthesis 
step, where in contrast, experiment 4 utilised three cycles. One full-length alternatively spliced 
isoform (Δ 9-10,14) was observed in experiment 4 (Figure 4.9), and only 2 full-length 
alternatively spliced isoforms (Δ 5,9 & Δ 9-10) were observed in the Nanopore RNA Consortium 
data (Table 4.3). While experiment 1 (control experiment) showed no isoforms with exon-
skipping, experiments 2 and 4 showed isoforms with exon-skipping events (Tables 4.3-4.4). Of 
note, none of the isoform types in experiment 4 were observed in the consortium data. 
Furthermore, short fragments such as exon 24-only transcripts (Figure 4.10) were observed in all 
experiments, except in experiment 4. Overall, counts and TPM for BRCA1 were low across all 










Table 4. 3 Manual counts of BRCA1 transcripts from all four experiments (NM_007294) 
Isoform Type Exp 1 Counts   Exp 2 Counts   Exp 4 Counts   Consortium Total 
Data 
Full length (∆ 5,9)    1 
Full length (∆ 9-10)     1 
Full length (∆ 9-10,14)     1  
Exon 1-6      2 13  
Exon 1-6 (∆ 5)         1  
Exon 1-7         5  
Exon 1-7(∆ 2-3)         1  
Exon 1-7 (∆ 5)         1  
Exon 1-11      1 1  
Exon 1-11(∆ 9-10)        2  
Exon 2-24    5 
Exon 2-24 (∆ 3,9)    1 
Exon 2-24 (∆ 9)    1 
Exon 2-24 (∆ 9-10)    1 
Exon 2-24 (∆ 22)    1 
Exon 6-24    1 
Exon 11      
Exon 11-24      22 
Exon 11-24 (∆ 14)      1     
Exon 11-24 (∆ 16-18,21-23)    1 
Exon 13-24      1    1 
Exon 13-24 (∆ 14)            3 
Exon 14   12        
Exon 14-24 (∆ 16-18)    1 
Exon 15-24    4 
Exon 16-24    7 
Exon 17    1        
Exon 17-24      1    3 
Exon 18-24    4 
Exon 20-24    2 
Exon 22-24    2 
Exon 23-24   1        
Exon 24 / UTR   9 3    45 
 




Table 4. 4 Transcripts per million of BRCA1 transcripts from all four experiments (NM_007294) 
Isoform Type  Exp 1 
Counts   
Exp 2 
Counts   
Exp 4 
Counts   
Consortium Total 
Data 
Full length (∆ 5,9)    < 1 
Full length (∆ 9-10)     < 1 
Full length (∆ 9-10,14)     1.54  
Exon 1-6      6.94 19.96  
Exon 1-4 (∆ 5)       1.54  
Exon 1-7       7.68  
Exon 1-7(∆ 2-3)       1.54  
Exon 1-7 (∆ 5)       1.54  
Exon 1-11      3.47 1.54  
Exon 1-11(∆ 9-10)      3.07  
Exon 2-24    0.49 
Exon 2-24 (∆ 3,9)    < 1 
Exon 2-24 (∆ 9)    < 1 
Exon 2-24 (∆ 9-10)    < 1 
Exon 2-24 (∆ 22)    < 1 
Exon 6-24    < 1 
Exon 11      
Exon 11-24      2.14 
Exon 11-24 (∆ 14)      3.47   
Exon 11-24 (∆ 16-18,21-23)    < 1 
Exon 13-24      3.47  < 1 
Exon 13-24 (∆ 14)        < 1 
Exon 14   22.23    
Exon 14-24 (∆ 16-18)    < 1 
Exon 15-24    < 1 
Exon 16-24    < 1 
Exon 17    1.85    
Exon 17-24    3.47  < 1 
Exon 18-24    < 1 
Exon 20-24    < 1 
Exon 22-24    < 1 
Exon 23-24   1.85    
Exon 24 / UTR   16.67 10.41  4.38 





The reference of the BRCA1 gene is enclosed in a red box. The isoform types observed in the experiments are directly below the full-length 
reference, with intron-exon information. Exons are indicated in blue blocks, and introns are indicated in black horizontal lines. No clear evidence 
of a 3’ or 5’ bias was present across experiments 1-4.   
Figure 4. 10 A schematic of observed BRCA1 isoform types across experiment 1-4 




4.8.2.2 CHEK2 transcript counts 
Low numbers of CHEK2 transcripts were observed across all datasets, along with 3’ bias. 
However, there was lack of evidence to conclude a 3’ bias for experiment 2. The absolute 
number of isoform counts was highest in experiment 4 (Table 4.5). Only two splice isoforms 
were found in all four experiments, with two ∆ 3 isoforms being found in experiment 2 (Table 
4.5). However, these transcripts were not full-length isoforms (exon 2-4, 2-16). The overall TPM 
for most transcript types was similar between experiments, however, the experimental TPMs 
were greater compared to the consortium dataset (Table 4.5). Only 3 types of transcripts (exon 
2-16, 13-16 and 14-16) were found in both experiments 1 and 4 (Table 4.5, Figure 4.11). This 
suggests that these datasets may not be comparable due to the low number of overlapping 














Table 4. 5 Manual counts of CHEK2 transcripts from all four experiments (NM_001257387) 
Isoform Type Exp 1 
Counts   
Exp 2 
Counts   
Exp 4 Counts   Consortium Total 
Data 
Full length            3 
Full length (▼2)       2 
Exon 2-4   1       3 
Exon 2-4 (▼2)       1 
Exon 2-4 (∆ 3)      1      
Exon 2-15       1 
Exon 2-16            33 
Exon 2-16 (▼2)       1 
Exon 2-16 (∆ 3)      1      
Exon 2-16 (∆ 6-7,11-15)       1 
Exon 3-15       1 
Exon 3-16       6 
Exon 4-6       1 
Exon 4-15       1 
Exon 4-16       2 
Exon 6-16       2 
Exon 7-16      1    2 
Exon 8-16   1         
Exon 9-16         3 1 
Exon 10-16         2 4 
Exon 11-12  1       
Exon 11-16   1       7 
Exon 12-16   2    2 5 
Exon 13-16   1    2 5 
Exon 14-16   2    4 1 
Exon 15-16         1 6 












Table 4. 6 Transcripts per million of CHEK2 transcripts from all four experiments (NM_001257387) 
Description   Exp 1 
Counts   
Exp 2 
Counts   
Exp 4 Counts   Consortium Total 
Data 
Full length            < 1 
Full length (▼ 2)       < 1 
Exon 2-4   1.85       < 1 
Exon 2-4 (▼2)       < 1 
Exon 2-4 (Δ 3)     3.47      
Exon 2-15       < 1 
Exon 2-16          3.20 
Exon 2-16 (▼ 2)       < 1 
Exon 2-16 (Δ 3)     3.47      
Exon 2-16 (Δ 6-7,11-15)       < 1 
Exon 3-15       < 1 
Exon 3-16       < 1 
Exon 4-6       < 1 
Exon 4-15       < 1 
Exon 4-16       < 1 
Exon 6-16       < 1 
Exon 7-16     3.47    < 1 
Exon 8-16   1.85        
Exon 9-16        4.61 < 1 
Exon 10-16        3.07 < 1 
Exon 11-12  1.85       
Exon 11-16   1.85      < 1 
Exon 12-16   3.71    3.070 < 1 
Exon 13-16   1.85    3.070 < 1 
Exon 14-16   3.71    6.14 < 1 
Exon 15-16         1.54 < 1 









The reference of the CHEK2 gene is enclosed in a red box. The isoform types observed in the experiments are directly below the full-length 
reference, with intron-exon information. Exons are indicated in blue blocks, and introns are indicated in black horizontal lines. 3’ bias was 
observed across the four experiments.  
Figure 4. 11 A schematic of observed CHEK2 isoform types across experiment 1-4 




4.8.2.3 GAPDH transcript counts 
3’ bias was observed in all experiments (Figure 4.12), with clear enrichment in experiment 2 and 
4 compared to experiment 1 (control experiment) (Table 4.7). The consortium subset data 
presented similar full-length transcript count levels as the enrichment experiments, however, all 
other types of isoforms presented greater counts in experiment 2 and 4 (Table 4.7). Spliced 
isoforms were rare across all experiments, with the most being found in experiment 4 (n=3) 
compared to experiment 2 (n=2) and experiment 1 (n=1) (Table 4.7). Higher TPMs were shown 
















Table 4. 7 Manual counts of GAPDH transcripts from all four experiments (NM_001289745) 
Isoform Type Exp 1 
Counts   
Exp 2 Counts   Exp 4 
Counts   
Consortium Subset 
Data   
Exon 1-9 (Full 
length)   
36 108 101 92 
Exon 1-9 (∆ 2)         1    
Exon 1-9 (∆ 4)         1    
Exon 1-9 (∆ 5)   1          
Exon 1-9 (∆ 7)         1    
Exon 2-9   91 241 197    
Exon 2-9 (∆ 5)      1       
Exon 3-9   48 199 240 109 
Exon 4-9   28 344 193 74 
Exon 5-9   29 189 141 34  
Exon 5-9 (∆ 6)      1       
Exon 6-9   59 304 225 94 
Exon 7-9    67 241 202 51 
Exon 8-9    292 875 734 232 













Table 4. 8 Transcripts per million of GAPDH transcripts from all four experiments (NM_001289745) 
Isoform Type Exp 1 
Counts   
Exp 2 Counts   Exp 4 Counts   Consortium Subset 
Data   
Exon 1-9 (Full 
length)   
66.69 374.87 155.08 252.92 
Exon 1-9 (∆ 2)       1.54   
Exon 1-9 (∆ 4)       1.54   
Exon 1-9 (∆ 5)   1.85       
Exon 1-9 (∆ 7)       1.54   
Exon 2-9   168.59 836.52 302.48   
Exon 2-9 (∆ 5)     3.47     
Exon 3-9   88.93 690.73 368.51 299.65 
Exon 4-9   51.87 1194.03 296.34 203.43 
Exon 5-9   53.73 656.02 216.50   
Exon 5-9 (∆ 6)     3.47     
Exon 6-9   109.30 1055.19 345.48 258.41 
Exon 7-9    124.13 836.52 310.16 140.20 
Exon 8-9    540.97 3037.14 1127.02 637.79 
Exon 9   35.20 482.47 150.47 68.73 
 
 






The reference of the GAPDH gene is enclosed in a red box. The isoforms types observed in the experiments are directly below the full-length 
reference, with intron-exon information. Intronic insertions are indicated in red blocks. 3’ bias was observed across the four experiments.  
 
Figure 4. 12 A schematic of observed GAPDH isoform types across experiment 1-4 




4.8.2.4 RAD51C transcript counts 
Full-length isoforms were observed for RAD51C in all experiments (Table 4.9, Figure 4.13). 
Experiment 1 showed 3’ bias, whereas bias information was unable to be obtained with 
experiment 2 due to the low number of transcripts. In contrast, experiment 4 presented even 
coverage across most types of isoforms, and therefore 3’ bias was less evident. This trend was 
also observed in the consortium data (Table 4.9). The absolute counts showed clear enrichment 
in experiment 4, when compared to experiment 1 (control experiment). Exon-skipping events 
were observed only for experiment 4, and the intronic insertions were only observed in 
experiment 1 (Table 4.9). All transcript types present in both experiment 1 and 4 show that there 
were higher TPMs in experiment 4 compared to experiment 1 across all transcripts. The TPM for 
full-length isoforms with no exon-skipping events were observed to be the highest in the 














Table 4. 9 Manual counts of RAD51C transcripts from all four experiments (NM_058216) 
Isoform Type Exp 1 Counts   Exp 2 Counts   Exp 4 Counts   Consortium 
Total Data 
Exon 1-9 (full length)   2 2 6 126 
Exon 1-9 (∆ 3)       1 
Exon 1-9 (∆ 3, 5-6)         1   
Exon 1-9 (∆ 4)         1 1 
Exon 1-9 (▼4)   1         
Exon 1-9 (∆ 4, 7)         2   
Exon 1-9 (∆ 6)         1   
Exon 1-9 (∆ 6-7)       1 
Exon 1-9 (∆ 7)         4 4 
Exon 1-9 (∆ 7-8)       2 
Exon 1-2   1 1 96   
Exon 1-6              
Exon 2         118 2 
Exon 2-9   1    28 20 
Exon 2-9 (∆ 3)         1 1 
Exon 2-9 (∆ 3-4)       1 
Exon 2-9 (∆ 3,7)         1   
Exon 2-9 (∆ 3-4,7)       1 
Exon 2-9 (∆ 4)         3 1 
Exon 2-9 (∆ 7)         7 1 
Exon 2-9 (∆ 7-8)   1         
Exon 2-3        1   
Exon 2-4        11   
Exon 2-5         1   
Exon 2-6         1   
Exon 3-9         13 15 
Exon 3-8   1    
Exon 4-9   4 1 21 8 
Exon 4-9 (▼4) 1         
Exon 4-9 (∆ 7)         1   
Exon 5-9         3 6 
Exon 5-9 (∆ 7)         2   
Exon 5-9 (∆ 7-8)         1   
Exon 5-6         1   
Exon 6-9         2 
Exon 6-9 (∆ 7)         1   
Exon 7-9         2 3 
Exon 7-9 (▼7)  1         
Exon 8-9   1    6 4 
Exon 9   3    7 5 
 
 




Table 4. 10 Transcripts per million of RAD51C transcripts from all four experiments (NM_058216) 
Isoform Type Exp 1 Counts   Exp 2 Counts   Exp 4 Counts   Consortium Total Data 
Exon 1-9 (full length)   3.71 6.94 9.21 12.23 
Exon 1-9 (∆ 3)       < 1 
Exon 1-9 (∆ 3, 5-6)       1.54   
Exon 1-9 (∆ 4)       1.54 < 1 
Exon 1-9 (▼4) 1.85       
Exon 1-9 (∆ 4, 7)       3.07   
Exon 1-9 (∆ 6)       1.54   
Exon 1-9 (∆ 6-7)       < 1 
Exon 1-9 (∆ 7)       6.14 < 1 
Exon 1-9 (∆ 7-8)       < 1 
Exon 1-2   1.85 3.47 147.40   
Exon 1-6           
Exon 2       181.18 < 1 
Exon 2-9   1.85   42.99 1.94 
Exon 2-9 (∆ 3)       1.54 < 1 
Exon 2-9 (∆ 3-4)       < 1 
Exon 2-9 (∆ 3-4,7)       < 1 
Exon 2-9 (∆ 3,7)       1.54   
Exon 2-9 (∆ 4)       4.61 < 1 
Exon 2-9 (∆ 7)       10.75 < 1 
Exon 2-9 (∆ 7-8)   1.85       
Exon 2-3      1.54   
Exon 2-4      16.89   
Exon 2-5       1.54   
Exon 2-6       1.54   
Exon 3-9       19.96 1.46 
Exon 3-8   1.85    
Exon 4-9   7.41 3.47 32.24 < 1 
Exon 4-9 (▼4)   1.85    
Exon 4-9 (∆ 7)        1.54   
Exon 5-9        4.61 < 1 
Exon 5-9 (∆ 7)        3.07   
Exon 5-9 (∆ 7-8)        1.54   
Exon 5-6        1.54   
Exon 6-9         < 1 
Exon 6-9 (∆ 7)        1.54   
Exon 7-9        3.07 < 1 
Exon 7-9 (▼7)  1.85        
Exon 8-9   1.85    9.21 < 1 
Exon 9   5.56    10.75 < 1 
 
 





The reference of the RAD51C gene is enclosed in a red box. The isoform types observed in the experiments are directly below the full-length 
reference, with intron-exon information. Exons are indicated in blue blocks, and introns are indicated in black horizontal lines. Intronic insertions 
are indicated in red blocks. 3’ bias was observed across the four experiments.  
Figure 4. 13 A schematic of observed RAD51C isoform types across experiment 1-4 




4.8.2.5 TPM isoform ratios 
To determine whether the enrichment experiments 2 and 4 were quantitative, the ratios of three 
GAPDH isoform types to full-length TPMs were examined across different experiments (Table 
4.11). Results revealed that these ratios were similar between experiments 2 and 4 (enrichment 
experiments) and experiment 1 (control experiment), suggesting linear enrichment.  
 
Table 4. 11 GAPDH isoform ratios of TPM 
Ratio of TPM Exp 1 (Control) Exp 2 
(Enrichment) 
Exp 4 (Enrichment) 
Exon 6-9 / Full length 1.64 2.81 2.23 
Exon 7-9 / Full length 1.86 2.23 2.00 
Exon 8-9 / Full length 8.11 8.10 7.27 
 
 
The ratios between different RAD51C isoform types across different experiments revealed 
dissimilar ratios between control and enrichment experiments (Table 4.12). The ratios between 
experiments 1-2 (control experiments) were similar; however, experiment 4 presented greater 
ratios. This was particularly shown in exon 1-2/full length ratios in experiment 4, which were 32-
fold greater than experiments 1-2 (control experiments). However, it is important to note that the 
accuracy of this comparison may be influenced by the very low number of reads in experiment 1 








Table 4. 12 RAD51C isoform ratios of TPM 
Ratio of TPM  Exp 1 (Control) Exp 2 (Control)* Exp 4 (Enrichment) 
Exon 4-9 / Full length 2 0.5 3.5 
Exon 1-2 / Full length 0.5 0.5 16 
*In experiment 2, only BRCA1 and GAPDH were enriched, so that RAD51C was not targeted for 
enrichment. Whereas in experiment 4, RAD51C was targeted for enrichment. Therefore, for the purposes 
of comparing whether experiment 4 enriched for RAD51C, the results of experiment 2 was regarded as a 




4.8.2.6. Comparison of alternative splicing events to other datasets 
All BRCA1 single-exon alternative splicing events (∆ 5, ∆ 14, ∆ 22) were detected in both the 
DRS data and the MCRG data. Furthermore, they have all been previously described in the 
literature (Table 4.13). In contrast, the exon-skipping events which occurred across longer 
distances such as ∆ 3, 9 were only detected in long-read DRS datasets. Other alternative splicing 
events, such as ∆ 5, 9, ∆ 16-18 and ∆ 16-18, 21-23 were only observed in the Nanopore RNA 
Consortium data, and were not previously described in other external datasets which utilised 









Table 4. 13 Comparison of BRCA1 alternative splicing events (NM_007294) with external datasets 













∆ 2-3   1   Colombo et al. (2014) 
∆ 3, 9    1  de Jong et al. (2017) 
∆ 5   2  8 Colombo et al. (2014) 
Lattimore et al. (2018) 
∆ 5, 9    1  - 
∆ 9    1  Colombo et al. (2014) 
Lattimore et al. (2018) 
∆ 9-10   2 2 8 Colombo et al. (2014) 
∆ 9-10, 14   1   de Jong et al. (2017) 
∆ 14  1  3 2 Colombo et al. (2014) 
∆ 16-18    1  - 
∆ 16-18, 21-23    1  - 
∆ 22    1 5 Colombo et al. (2014) 
Lattimore et al. (2018) 
*Mackenzie Cancer Research Group, University of Otago, Christchurch 
 
Only a small number of CHEK2 alternative splicing events were observed across all datasets 
(Table 4.14). ∆ 3 was observed in experiment 2 and was previously described (Davy et al., 
2017). The Nanopore RNA Consortium dataset consisted of multiple ▼ 2 insertions.  
 















▼2    4  - 
∆3  2    Davy et al 
(2017) 









GAPDH mRNA splicing events ∆ 2 and ∆ 7 were both found in experiment 4 and MCRG RNA-
seq data (Table 4.15). In contrast, ∆ 4, ∆ 5 and ∆ 6 were only observed in experiments 1-4. None 
of these isoforms have been described in the literature to my knowledge. Exon-skipping co-
occurrence was not observed in any single transcript, and alternative splicing events were not 
found in the Nanopore RNA Consortium subset data.  
 
















∆2   1  33 - 
∆4   1   - 
∆5 1 2    - 
∆6  1    - 












∆ 3, ∆ 4, ∆ 6, ∆ 7, and ∆ 7-8 were observed in the RAD51C DRS enrichment data (Table 4.16) 
and MCRG RNA-seq data (unpublished), where they have all been previously described by 
Davy et al. (2017). However, alternative splicing events (∆ 3,5-6, ∆ 3,7 and ∆ 4,7) were only 
observed in experiment 4 and were not previously described (Table 4.16). Furthermore, insertion 
events were only found in experiment 1.  
 
 
















∆3   1 2 65 Davy et al. (2017) 
∆3-4    1  - 
∆3-4,7    1  - 
∆3,5-6   1   - 
∆3,7   1   - 
∆4   4  16 Davy et al. (2017) 
▼4 2     - 
∆4,7   2   - 
∆6   1  7 Davy et al. (2017) 
∆6-7    1  Davy et al. (2017) 
▼6 1     - 
∆7   15 5 50 Davy et al. (2017) 













Experiment 2 was the first attempt at enrichment using the T7 RNA polymerase binding site 
attached to a gene specific primer method, which targeted two genes (BRCA1 and GAPDH). In 
experiment 2, the results on IGV showed considerable amplification of GAPDH. However, there 
was no clear evidence of clear amplification, nor full-length transcripts for BRCA1.  
 
Experiment 3 was used as an attempt to enrich transcripts from 12 hereditary breast and ovarian 
cancer genes (Table 1.1), but experiment 3 results revealed less than the expected number of 
reads compared to all other experiments, and was omitted from the rest of the study. Reasons for 
this poor outcome may be due to the pooling of T7-GSP primers in one reaction during the 
second cDNA strand synthesis step, and utilising only one PCR cycle in the same step. 
 
Experiment 4 consisted of a smaller panel of genes compared to experiment 3, which included 
BRCA1, GAPDH, CHEK2 and RAD51C. This experiment proved to be the most successful 
enrichment experiment of all attempted experiments due to many factors. In experiment 4, the 
novel methodological technique conducted in this study gave rise to considerable enrichment of 
GAPDH and RAD51C, and less obvious amplification for CHEK2 and BRCA1. Importantly, 
GAPDH results revealed evidence of linear enrichment, through calculating TPM ratios between 
experiments (Table 4.11).  
 




Bioinformatics proved to be difficult, especially with quantifying long DRS reads. However, via 
manual counting, it appeared that the MinION DRS data was able to detect multiple exon-
skipping events in the same transcript across long distances for RAD51C, which have not been 
previously described in literature (Table 4.16). The results of these experiments will be fully 
discussed in chapter 5.  
 
4.9.2 RNA source/cell culturing 
LCLs are immortalized cells which have been derived from peripheral blood lymphocytes that 
have been infected by an Epstein-Bar virus (Neitzel, 1986). They have been routinely used as a 
continuous source of DNA, RNA and proteins, and is known to express BRCA1 in relatively high 
quantities (https://gtexportal.org/home/gene/BRCA1). The particular control LCL (Table 2.1) 
was chosen to be implemented in this study due to previous work being done in this laboratory 
using the same cell line (de Jong et al., 2017). RNA was extracted from these LCL with an 
RNeasy® Mini Kit, and was checked for quality. Tapestation RINe scores are measures of RNA 
quality, which are derived from algorithms determining the quantitative measurement of RNA 
degradation (Agilent Technologies, 2016). The extracted total RNA showed RINe scores of 
above 9.3 across all extractions, which proved that the quality of starting RNA was satisfactory 
for downstream usage. Poly-A RNA (mRNA) was further isolated from total RNA in 
Experiment 1, which revealed a total amount of 151.2 ng of mRNA. Typically, mRNA 
contributes to 1-5% of the total eukaryotic RNA concentration (Rosenow, Saxena, Durst, & 
Gingeras, 2001). Compared to the total RNA input amount, the mRNA obtained from this 
mRNA isolation step was not satisfactory, therefore, the mRNA isolation step was omitted in 
successive experiments.  




NMD inhibition was carried out for 4 hours before the process of RNA extraction in all 
experiments. The NMD inhibitor was used to prevent degradation of transcripts with premature 
protein truncations, which would normally be degraded by the NMD surveillance mechanism. 
Gene expression levels are dependent on many factors, including environmental stress (Murray 
et al., 2004). It has been suggested that using an NMD inhibitor may change the expression level 
of certain transcripts by overloading the endoplasmic reticulum with truncated misfolded 
proteins, which would cause an increase in cellular stress, although this remains to be proven 
(Hug, Longman, & Caceres, 2016). Furthermore, it is worth noting that expression data 
generated from cells exposed to NMD inhibitors may not be comparable to expression data from 
breast cancer tissues. 
 
4.9.3 First strand cDNA synthesis 
4.9.3.1 Standard long-range PCR vs alternative long-range PCR 
Long-range PCR was carried out to confirm the presence of full-length BRCA1 isoforms, as it 
was the primary gene of interest in the study. However, this was not carried out for other genes 
of interest, due to the availability of time and resources. In the results of the standard long-range 
PCR, one agarose gel showed presence of a prominent band around 2.4 KB (Figure 4.2 A), 
which was also observed in Fig. 4.2 B. These bands may be attributed to full-length isoforms 
which lack exon 11, the largest exon in the gene. Exon 11 is 3.4 KB long and contains the 
RAD51-interaction domain, which is involved in the double-stranded DNA break repair 
mechanism (Tammaro et al., 2012). The ∆ 11 isoform has been previously described in the 
literature, where mouse embryonic fibroblast cells which were homozygous for the ∆ 11 isoform 




showed a deficient G2-M checkpoint (X. Xu et al., 1999). Full-length BRCA1 products without 
skipping were only observed in Fig. 4.2 B, and was represented by a faint, thin band of around 6 
KB. This suggests that full-length isoforms were present in the sample, and the first cDNA 
strand synthesis proved to be successful. Given that full-length BRCA1 isoforms were present in 
the sample, it can be inferred that other genes of interest with higher expression levels and 
shorter transcript lengths were also present in our sample, such as RAD51C and GAPDH (Table 
4.1). The inconsistency between the two standard long-range PCR and the other failed 11 PCR 
results may have been generated due to the inconsistencies in aliquoting the BRCA1 cDNA and 
different rates of degradation. In contrast, the results of the alternative PCR revealed improved 
outcomes, with full-length products of around 5.8 KB and what is assumed to be the Δ11 isoform 
of BRCA1 with a length of approximately 2.4 KB (Raponi et al., 2014) (Figure 4.3). These 
bands were more prominent and brighter compared to the standard long-range PCR counterparts. 
This suggests that the alternative long-range PCR method incorporated better PCR cycling 
conditions, or improved ratios of reagents compared to the standard long-range PCR. The 
alternative long-range PCR involved a higher MgCl2 and cDNA concentrations, and lower 
concentration of dNTP mix, with shorter denaturation and extension times compared to the 
standard long-range PCR. Higher MgCl2 concentrations have been associated with a greater 
yield, but also a decrease in specificity (Lorenz, 2012). Furthermore, higher dNTP concentrations 
can inhibit the PCR reaction, which may explain the inferior results of the standard long-range 
PCR (Lorenz, 2012). As only one alternative long-range PCR was carried out, these comments 
are inconclusive, hence more reactions should be carried out in the future to validate this claim. 
The amount of input RNA was maintained at the maximum possible level of 5 µg per reaction to 
standardise our experiments during the first strand synthesis step.  




4.9.4 Second strand cDNA synthesis 
4.9.4.1 Temperature gradient PCR 
The temperature gradient PCR was carried out in order to find the optimum annealing 
temperature for the second cDNA synthesis. The resulting gel revealed bright and prominent 
bands between 49.8 °C and 62.0 °C for BRCA1 (Figure 4.4), and between 49.8 °C and 65.1 °C 
for GAPDH (Figure 4.5). The lowest integer temperature of the brightest bands was used in all 
second cDNA synthesis experiments, which was 50 °C for both BRCA1 and GAPDH. If the 
annealing temperature is high, there is a chance of non-specific annealing, and if inadequate, it 
may cause decrease in yield (Rychlik, Spencer, & Rhoads, 1990).  Ideally, this temperature 
gradient experiment should have been carried out for all genes studied in this project, however, 
lack of time and resources prevented this from occurring. Therefore, this may have limited the 
outcomes of the second cDNA strand synthesis step. One reason which could explain the poor 
outcomes of experiment 3, may be the use of one annealing temperature for many different T7-
GSP primers, all with differing Tm values (Table 2.2). This also implies that experiment 4 may 









4.9.4.2 T7-only primer PCR 
The T7-only primer PCR was carried out with T7-only forward and exon 7 reverse primers for 
BRCA1 products, to assess the incorporation of the T7 RNA polymerase binding site at the 5’ of 
the second cDNA strand. The gel proved that the incorporation had taken place successfully as a 
clear band of the correct approximate size was visualised (Figure 4.7).   
 
4.9.4.3 T7-oligo dT(20) (full-length) PCR 
The purpose of this PCR was to determine if full-length transcription had taken place in the 
second cDNA strand synthesis step in experiment 4. It is clear that GAPDH, RAD51C and 
CHEK2 showed full-length double stranded cDNA molecules in the sample, with approximate 
sizes of 1.2 KB to 1.9 KB (Figure 4.9). However, it was unclear whether there were full-length 
BRCA1 double stranded cDNA molecules in the sample, as the gel did not show clear bands 
around 5.8 KB or greater. These results correspond to the relative expression levels of these 
genes (Table 4.1). RAD51C and CHEK2 products presented numerous faint but distinct bands 
above 1.3 KB, which indicate that many types of isoforms of RAD51C and CHEK2 were present 








4.9.5 HighPrep™ magnetic bead clean-up 
In experiment 2, Qubit™ dsDNA HS assays results revealed low and similar dsDNA 
concentrations for both BRCA1 and GAPDH samples of 1.97 ng/µL and 1.96 ng/µL, 
respectively. This was an unexpected result, as GAPDH has a higher expression compared to 
BRCA1 (Table 4.1). As the optimum annealing temperatures have been determined for both 
these genes (Figures 4.4-4.5), it appears that these results were not a consequence of suboptimal 
annealing temperatures during the second cDNA synthesis step. One possible explanation for 
these results, may be due to the inaccurate sampling of a small volume (1 µL) using a pipette 
during the Qubit™ assay step.  
In experiment 3, an attempt was made to enrich a panel of 12 different hereditary breast and 
ovarian cancer genes. The T7-GSP for all 12 genes were pooled and the reaction was carried out 
in a single tube. The final Qubit™ dsDNA HS assay results showed a higher concentration (16.6 
ng/µL) compared to the second experiment. However, assuming that each gene in the panel 
equally contributed to these results, the average dsDNA concentration of each gene would be 
1.38 ng/µL, which is a poor outcome compared to the results of experiment 2. Although it is 
unclear why this experiment failed, it is possible the pooling step lead to suboptimal outcomes. 
For that reason, the pooling approach was not used in experiment 4. 
In experiment 4, four different reaction volumes were carried separately through the second 
cDNA strand synthesis step, with one reaction for each gene of interest; GAPDH, BRCA1, 
RAD51C, CHEK2. RAD51C and CHEK2 are hereditary breast and ovarian cancer genes with 
similar transcript lengths to GAPDH (Table 4.1). Through this experiment, the effect of gene 
expression on the efficacy of the novel enrichment method was tested. Three cycles of PCR were 
implemented only in this experiment in the second strand synthesis step, to increase the effect of 




enrichment. This increase in the number of cycles was expected to maintain linear amplification 
due to the use of unidirectional PCR. Furthermore, the Qubit™ dsDNA HS assay results 
exhibited approximately 6-fold increase of dsDNA concentration of BRCA1 and GAPDH in this 
experiment compared to the results of experiment 2. The results provided evidence to suggest 
that the increase in the number of PCR cycles within the second strand synthesis step contributed 
to a higher yield. Interestingly, the dsDNA concentrations of all genes in this panel were similar, 
which reflects the results in experiment 2. Therefore, repeating these experiments may provide a 
clearer assessment of these results. Furthermore, there is a possibility that insufficient magnetic 
bead elution caused some loss of product, which would also confound the results.  
 
4.9.6 In vitro transcription & RNAClean™ XP magnetic bead clean-up 
The incubation times during in vitro transcription for the 2nd and 3rd experiments were 4 hours 
and 16 hours respectively, as the manufacturer’s guidelines indicated that the incubation step 
should be carried out around 4-16 hours. Therefore, the two extremes of incubation time were 
tested in these experiments. However, as experiment 3 generated insufficient data to compare 
with experiment 2, the results were unable to be compared.  
To determine whether further incubation time maximised the probability of detecting longer 
transcripts, 20 hours of incubation was trialled in the in vitro transcription step. It was evident 
that experiment 4 produced the most transcripts among all four experiments, and therefore this 
step may play a critical role within the enrichment process.  
As with the HighPrep™ magnetic bead clean-up step, the RNAClean™ XP magnetic bead clean-
up process increased the chances of losing in vitro transcribed RNA via insufficient eluting of 




beads. The results of the Qubit™ RNA HS assay revealed the greatest concentrations of RNA in 
experiment 4, and the lowest concentration in experiment 3. Therefore, the concentration of the 
in vitro RNA was not directly proportional to the incubation time, which may suggest that further 
testing needs to be carried out to validate this concept with experiments which only vary in the 
incubation time. In all experiments, the concentration of the input RNA levels was lower 
compared to the recommended amount of RNA (500 ng) described in the ONT protocol 
(Appendix H). This may have contributed some artifacts in the sequencing step. The dsDNA 
concentrations within the library preparation step followed the same trend, with the highest 
levels of dsDNA concentrations presented in experiment 4. The recommended recovery is up to 















Chapter 5: Discussion 
5.1 Introduction 
Initially, the main purpose of this project was to develop and test a novel method of linearly 
enriching BRCA1 transcripts, and to make use of the new opportunities afforded by direct RNA 
sequencing on the MinION nanopore sequencer. The original motive for this enrichment was to 
enable the study of effects of VUS on alternative splicing patterns of BRCA1. Over the course of 
the project, the scope expanded to a wider range of genes, which included GAPDH and other 
associated hereditary breast and ovarian cancer genes (Table 1.1). The two major components of 
the project consisted of laboratory experiments and bioinformatic analyses.  
 
5.2 Rationale  
The first experiment was a proof-of-principle experiment whereby the efficacy of the MinION 
DRS method was tested. This experiment was set as the reference experiment for subsequent 
experiments. Experiments 2-4 were carried out to test a novel linear amplification method for 
targeted RNA transcripts. In the second experiment, BRCA1 was the gene of interest, and 
GAPDH was used as a control gene. Building on the results of the second experiment, the third 
experiment involved testing a panel of hereditary breast and ovarian cancer genes, with a range 
of different expression levels and transcript lengths, to test the limits of the novel linear 
amplification method. The fourth experiment involved a panel of four genes; GAPDH, RAD51C, 
BRCA1, and CHEK2, with the latter three with biological relevance to breast cancer and wide 
range of expression levels. RAD51C and CHEK2 have similar transcript lengths and different 
expression levels to GAPDH (Table 4.1) and were utilised to evaluate the effect of gene 




expression on this novel enrichment method. Below I discuss each key component of this 
project. 
 
5.3. Direct RNA Sequencing (DRS)  
As explained previously, DRS is a novel approach and its efficacy has not been validated as 
much as traditional RNA-seq. The first hypothesis of this project was that DRS was able to be 
carried out in a proof-of-principle experiment (experiment 1).  
 
The results from this experiment revealed that DRS was successful with the RNA that was 
extracted in this laboratory (Figures 3.2-3.9). Therefore, it may be concluded that the relatively 
novel DRS kit is able to be carried out with relative ease. The outcome of 889,850 sequenced 
RNA reads in experiment 1 support this, as this is a comparable number to the Nanopore RNA 
Consortium data (Table 2.4).  
 
5.4. Novel enrichment method  
Through carrying out experiments 2-4, a novel enrichment approach was developed and tested. 
The enrichment method involved RNA extraction, first cDNA strand synthesis, second cDNA 
strand synthesis, in vitro transcription and MinION sequencing (Figures 3.1, 4.1). Experiment 2 
and 4 proved to show positive outcomes of enrichment, whereas experiment 3 did not produce 
outcomes that were able to be compared with other datasets (Tables 4.3-4.10).  
 




GAPDH and RAD51C, which have shorter transcript lengths and greater expression levels 
compared to BRCA1 and CHEK2 (Table 4.1), were able to be clearly enriched through this novel 
enrichment method. The specific details of these results are outlined below in sections 5.6-5.10.  
 
5.5. Bioinformatic analyses  
Bioinformatic analyses proved to be challenging due to the lack of availability of software 
specific for long-read DRS. This is almost certainly due to the novelty of this platform, and it is 
likely that more appropriate software will be rapidly developed due to the wide uptake of 
nanopore sequencing. In this thesis, software which was designed for short RNA-seq data or long 
RNA-seq data was trialled with the data generated from our DRS nanopore sequencing 
experiment.  
 
Data acquisition with MinKNOW and Albacore was carried out with ease, as the software was 
provided by ONT. Basecalling with Albacore produced ‘pass’ and ‘fail’ reads, in which the 
number of ‘pass’ reads were greater than ‘fail’ reads in all experiments except experiment 3. Pass 
reads have a quality score of > Q7, and this result suggests that the quality of RNA in experiment 
3 was suboptimal.  
 
Databases and indices were successfully created with all four tested alignment programmes 
(Minimap2, BLAT, GMAP, LAST), however, alignment was only successfully carried out with 
Minimap2. Four quantification programmes (Kallisto, Salmon, Mandalorion and SQANTI) were 




tested, and the results revealed that the parameters used within these programmes were unable to 
quantify long DRS reads produced by the MinION (Tables 3.9-3.14).  
 
 
The final pipeline used for analysing the reads generated from experiments 1-4 involved aligning 
the reads with Minimap2 with the given ONT DRS parameters, sorting and indexing with 
Samtools, and visualizing the file on IGV. The reads were manually counted and categorized. 
The specific details of the analyses are outlined below in sections 5.6-5.10. 
 
 
5.6 BRCA1 transcripts  
BRCA1 was the initial focus of the thesis, and as expected, BRCA1 was very poorly represented 
(Tables 4.3-4.4). Interestingly, many short transcripts located in the middle of the gene were 
observed in experiment 1 (Figure 3.2). Upon closer examination of these short mid-gene located 
reads, poly-A regions were found in the corresponding intronic region of BRCA1. This may have 
caused spurious alignment of gDNA contaminants or creation of truncated cDNA during first 
strand synthesis by the oligo-dT primer binding to these intronic poly-A region (length = 16 bps) 
(Nam et al., 2002). This has been additionally confirmed by studying these reads with the online 
UCSC Genome Browser BLAT tool. The short regions appeared to align to various genes, not 
only for BRCA1. Furthermore, this region was not recognised to be a retroviral element or 
retrotransposon by the UCSC Genome Browser repeat tracks.  




There was lack of evidence to determine whether there was any 5’ or 3’ bias in experiments 1 
and 2. In the second experiment, while reads from the 5’ side of the RNA were present, other 
reads started from the middle of the gene in exons 11, 13 and 17 (Table 4.3, Figure 4.10). This 
phenomenon may also be explained by non-specific binding of the T7-GSP to the middle of the 
gene instead of the 5’ end, or the premature interruption of sequencing. BRCA1 appeared to be 
enriched in the 4th experiment, with a 5’ bias, which was an unexpected result. The truncated 3’ 
ends of these reads may indicate that the LongAmp® Taq polymerase may have not been able to 
fully transcribe to the 3’end of the gene, or the T7 RNA polymerase may have prematurely 
detached from the double stranded cDNA.  However, these explanations do not justify the fact 
that reads without poly-A tails have been able to be sequenced with nanopore sequencing, which 
requires 3’ poly-A tails for the attachment of adapters. This suggests that perhaps the nanopores 
are non-specific and are prone to drawing in molecules without adapters. Otherwise, the 
transcripts could have fused to the adapters spontaneously during sequencing.  
 
The fourth experiment was also able to produce a full-length alternatively spliced BRCA1 
isoform (Δ 9-10, 14), whereas only two full-length alternatively spliced isoforms were found in 
the consortium dataset (Δ 5,9, Δ 9-10) (Table 4.3). Considering that the consortium dataset 
consisted of around 13 million reads from 30 MinION flow-cells which greatly exceeded the 
number of reads from the Experiment 4, this enrichment technique appears to be promising. 
Furthermore, longer transcripts were found in Experiment 4 compared to Experiments 1-2. This 
provides evidence that the protocol for the fourth experiment may be a good starting point for 
further development.  
 




Exon-skipping events were only observed in the enrichment experiments (Table 4.13), which 
suggests that the enrichment method may enable a wider range of transcripts to be observed. 
However, this may also suggest that the increased number of manipulations have caused spurious 
alignment and introduced errors in the data. In other respects, as the Nanopore RNA Consortium 
dataset also contained BRCA1 transcripts with exon-skipping events, this may suggest that in 
fact, the lack of data in the first experiment prevented the observation of these events. 
Furthermore, the isoform types observed in experiment 4 were not observed in the consortium 
data. This may be attributed to the fact that most of the 5’ reads in experiment 4 were truncated 
(Figure 4.10, Table 4.3), whereas the Nanopore RNA Consortium dataset did not contain 3’ 
truncations in general. Therefore, these differences may have occurred from using numerous 
manipulations in experiment 4, as opposed to a few manipulations used to generate the Nanopore 
RNA Consortium dataset.  
 
5.7 CHEK2 transcripts 
CHEK2 is recognised as a gene with an even lower expression level compared to BRCA1, which 
is reflected by the low number of counts in Table 4.5. 3’ bias was observed, which may be 
explained by the use of an oligo-dT primer, which may have contributed to the truncated reads. 
CHEK2 transcripts in experiment 4 did not show a 5’ bias such as with BRCA1 transcripts, which 
may be attributed to the shorter transcript length of CHEK2 compared to BRCA1 transcripts. It 
can be hypothesised that shorter transcripts provide less opportunities for error and reduce the 
likelihood of fragmentation prior or during sequencing. It was difficult to observe a 5’ or 3’ bias 
with experiment 2, due to the lack of data (Table 4.5). Overall, low number of alternative 
splicing events were observed across all datasets. Furthermore, as the variety of transcript types 




were different between datasets (experiments 1-4), the datasets were not comparable. Therefore, 
it was difficult to determine the efficacy of the enrichment method with CHEK2. Moreover, a 
considerable number of CHEK2 transcripts started from exon 2, as opposed to exon 1 in the 
consortium data. This may suggest that there is a presence of an alternative promoter within exon 
2. Assuming that this is true, this would suggest that the T7-GSP primer has an efficacy for 
binding to the start of exon 2 as well as exon 1. This result was predictable as approximately 
52% of RefSeq genes are subjected to putative alternative promoters (Kimura et al., 2006). 
Furthermore, 65 % of all promoters are within 500 bps of a CpG island, and 95 % of all 
promoters are within 10 KB of a CpG island (J. Wang, Ungar, Tseng, & Hannenhalli, 2007). 
Upon closer examination, a CpG island (CpG : 53) was found within 50 bps of exon 1, and 
revealed to show a high level of the H3K4Me3 mark, which is indicative of the presence of 
promoters. However, exon 2 did not show any considerable level of the mark, which indicates 
that exon 2 is unlikely to carry an alternative promoter site. A more feasible idea to explain the 
results (Table 4.5) may be that the in vitro RNA may have been fragmented at the junction of 
exon 1 and 2, or sequenced partially by the MinION.  
 
5.8 GAPDH transcripts 
GAPDH is a control housekeeping gene with high expression, and a short transcript length. Full-
length GAPDH transcripts were abundant in various runs (Table 4.7). There was clear 
enrichment in both experiment 2 and 4 compared to the control experiment. In particular, the 
normalised ratios between different type of GAPDH isoforms across different experiments were 
similar (Table 4.11). This is potential evidence of linear amplification. These results collectively 
suggest that the enrichment method was successful and has the potential to deliver linear 




amplification for genes of interest with careful optimisation. Only a subset of the MinION 
consortium data was used for comparison with GAPDH due time restraints. This subset data was 
also normalised to minimise the variation in the datasets.  
 
5.9 RAD51C transcripts 
RAD51C has a moderate level of expression and has a similar transcript length to GAPDH.  This 
was well reflected across all datasets, where numerous full-length isoforms were observed. 
Experiment 1 showed clear 3’ bias, whereas this bias was less evident in the other datasets 
(Table 4.9). This was due to the lack of data from the second experiment, and a wide distribution 
of isoform types in experiment 4 and the consortium dataset (Table 4.9). The absolute counts 
and TPM suggest a clear enrichment in experiment 4 compared to all other datasets (Tables 4.9-
4.10). This supports the fact that the protocol of the fourth experiment would be a good basis for 
future work. The enrichment outcomes appeared to be superior with RAD51C compared to the 
results of BRCA1 and CHEK2, and this may be associated with the higher expression level and 
short transcript length of the gene (Table 4.1). Exon-skipping events were observed in 
experiment 4 and the MinION consortium dataset, and not in the smaller datasets of experiment 
1 and 2. Intronic insertion events were observed only in experiment 1, which may be due to 
errors in alignment, or through an alternative splicing event (Cartegni et al., 2002).  There was no 
evidence for linear enrichment of different isoforms in the fourth experiment, as the ratios 
between different types of isoforms across different experiments were inconsistent (Table 4.12).  
 




5.10 Comparison of observed alternative splicing events with external 
datasets 
As there were differences in the mRNA isolation step between the control and enrichment 
experiments, comparisons were made with external datasets to test the validity of the data. Each 
external dataset used different combinations of LCL, with and without NMD inhibition. The data 
published by Colombo et al. (2014) presented RNA-seq data from whole blood leukocytes, 
Ficoll-isolated peripheral blood mononuclear cells, primary cultures of stimulated peripheral 
blood lymphocytes and LCLs. Lattimore et al (2018) presented RNA-seq data on various LCLs 
with the same NMD inhibition utilised in experiments 1-4. The work of de Jong, et al. (2017), 
from this laboratory, revealed exon-skipping co-occurrence in BRCA1 with long RNA-seq using 
the MinION. This data utilised the same LCL with NMD inhibition as experiments 1-4. Davy et 
al. (2017) data presented RNA-seq data from RNA extracted from various control and patient 
LCL without NMD inhibiton. The Nanopore RNA Consortium data, the only other study which 
used DRS, utilised a different LCL without NMD inhibition, and the MCRG RNA-seq data used 
a different LCL as experiments 1-4 with and without NMD inhibition. Due to these variations, 
these datasets may prove to be inefficient for comparing the data produced by this project. 
However, using them collectively provided a satisfactory comparison.  
 
BRCA1 is a well-studied gene, and therefore most alternatively spliced isoforms detected in this 
project were described previously in the literature (Colombo et al., 2014; Davy et al., 2017; 
Lattimore et al., 2018). Non-described isoforms with multiple exon-skipping events along further 
distances were only detected in the Nanopore RNA Consortium total data (Table 4.13). 




Alternative splicing events were scarce with CHEK2 datasets, and insertion events in intron 2 
and splicing of exons 6-7, 11-15 were observed in the consortium total data, but were not present 
in the published data mentioned above (Table 4.14). Novel RAD51C isoforms (Δ3,5-6, Δ3,7 and 
Δ4,7) not previously described in literature were found in my experiments (Table 4.16). The 
functional significance of alternative splicing within CHEK2 and RAD51C transcripts has been 
documented (Janatova et al., 2015; Staalesen et al., 2004). Across all GAPDH datasets, only 
single exon-skipping events were observed. These events were only recognised in experiments 1-
4 and the MCRG RNA-seq dataset, and do not appear to have been specifically reported 
elsewhere. However, they were able to be visualized in the ENCODE Caltech RNA-seq (Release 
2) dataset on the UCSC genome browser. Interestingly, the consortium subset data did not show 
any splicing events in GAPDH (Table 4.15). These differences may be attributable to the use of 
NMD inhibitors in experiments 1-4 and the MCRG RNA-seq dataset. As NMD inhibitors 
prevent NMD mechanisms degrading truncated or aberrantly spliced transcripts, this may have 
caused the NMD inhibited dataset to present exon splicing events. The non-NMD inhibition data 
from the same MCRG dataset supports this claim as it contained fewer skipping events compared 
to the NMD inhibited dataset (Appendix I). Novel GAPDH isoforms in a mouse model have 
been reported, (Menon et al., 2009) however, no report describing human GAPDH isoforms was 
evident in the literature. Overall, these results confirm that the nanopore DRS method is able to 
provide useful information on novel splice isoforms and exon-skipping co-occurrence. 
 
 




5.11 Limitations and future directions 
Accuracy limits the feasibility of this enrichment method, in its current form, to be used for 
classifying VUS which impact on splicing. Firstly, the high number of manipulations carried out 
in the enrichment method was a potential source of artifacts within the results. These include 
sample preparation, library preparation, sequencing and downstream bioinformatics processing 
steps, which may be mitigated by implementing replications such as biological, technical, and 
cross-sequencing-platform replications (Robasky, Lewis, & Church, 2013). For instance, a single 
sequencing platform is not sufficient for deriving accurate variant calling of Single Nucleotide 
Polymorphisms (SNP) (Ratan et al., 2013). Therefore, using multiple sequencing platforms for 
comparison could be valuable, although this will increase costs. These experiments also 
employed 1D nanopore sequencing, which is known to be error prone (> 20 %) (Ip et al., 2015). 
Furthermore, counting and sorting isoforms manually may have introduced human error. 
Therefore, collectively, these sources of potential artifacts may have influenced the results 
obtained. Improving these aspects of the procedure would be important goals for future work.   
 
Due to the limitations in time and resources, less than the optimum number of reactions were 
carried out through this project. Alternative long-range PCR, temperature gradient PCR, T7-
primer PCR and T7 and oligo dT(20) primer PCR were not carried out in all relevant cases. 
Performing these quality control approaches will be imperative for future evaluation of the 
enrichment method.    
 




Additionally, RNA is an unstable molecule compared to DNA and proteins. Therefore, there 
were many chances of RNA degradation throughout the experimentation process, which included 
freeze-thawing, and pipetting with fine tips. However, a study suggests that degradation of RNA 
derived from cancer tissue was less affected by freeze-thaw cycles compared to para-cancerous 
tissue RNA (Hu et al., 2017). This suggests that perhaps, the application of this method on 
biopsied breast cancer tissue may be less prone to freeze-thaw cycles compared to control LCLs 
(Hu et al., 2017).  
 
 
Future experiments could include using this approach with other cell lines with known variants, 
which could be used to optimise the efficacy. These cells lines may be chosen from previous 
experiments described in the literature so that direct comparisons can be made (Colombo et al., 
2014; Davy et al., 2017). Furthermore, this experiment could be tested with breast cancer tissue 
samples to further validate the approach. Carrying out the first experiment with total RNA 
instead of total mRNA may provide a better alternative for a reference experiment. Moreover, it 
would be beneficial to repeat the third experiment without pooling of T7-GSP and increasing the 
time of in vitro transcription incubation. Testing the effect of extra PCR cycles in the second 
strand cDNA synthesis step and incubation time in the in vitro transcription step may also 
provide beneficial information.  
 
As RT-qPCR methods are able to provide a quantitative method for quantifying isoforms, the 
novel enrichment method should be compared with these methods. Using RT-qPCR probes 




which span exon-exon junctions for all query genes will be critical to avoid the need for DNAse-
treatment, which proved to be detrimental (Barber, Harmer, Coleman, & Clark, 2005). While the 
datasets produced by this project were successfully aligned with Mimimap2, further development 
of quantification and alignment pipelines will be vital for future nanopore DRS research. As 
traditional RNA-seq data present with a length bias for longer genes (Oshlack & Wakefield, 
2009), a normalisation approach for minimizing this bias may also be beneficial for comparing 
with DRS data in future studies. This could include utilising Reads Per Kilobase Million 
(RPKM) instead of TPM. It is unclear whether there is a length bias in DRS, as the coupling of a 
long-read sequencer such as the MinION may mitigate the length bias. Therefore, examining two 
genes with the same expression level and different transcript lengths may provide more evidence. 
 
Additionally, the enrichment method incorporated a cDNA conversion and an in vitro 
transcription step, which lead to a loss of the ability to observe RNA modification. The ability to 
visualise RNA modifications is a key advantage of DRS, and therefore the loss of RNA 
modification information in the enrichment method was a limiting factor. Therefore, exploring 









5.12 Conclusions  
In this project, a novel RNA isoform enrichment method was developed and trialled with RNA 
extracted from a control LCL. The advantages of using this method lie in being able to visualise 
RNA isoform information for a set of specific genes of interest, and potentially to quantify these 
isoforms. If developed further, this method may be useful in clinical laboratory settings for 
providing more information to classify VUS that affect splicing and could be further utilised in 
many applications beyond cancer or the biomedical setting. 
 
Through testing a panel of different genes, we found that RAD51C and GAPDH were able to be 
enriched with this novel method. It was not clear whether enrichment of BRCA1 and CHEK2 had 
occurred due to the lack of isoform type comparability between datasets. However, the absolute 
number of BRCA1 and CHEK2 counts were greater in experiment 4 compared to the control 
experiment, and the enrichment in the same experiments observed with RAD51C and GAPDH 
suggests that this method warrants further investigation. Whether this method is linear (i.e. 
maintains the isoform diversity that exists in vivo) is subject to debate, however, our preliminary 
bioinformatic evidence suggests that GAPDH isoforms were enriched in a linear fashion. This 
suggests that the method can be optimised for use in the future with genes such as BRCA1 and 
may be used in the context of other diseases. Therefore, with successful optimisation, this novel 
enrichment method may be a valuable method to be used in studying VUS effects on alternative 
splicing patterns.  
 




In summary, further research into this method may provide new tools for studying the effects of 
VUS on alternative splicing patterns, allowing an improved method of classifying VUS that 
impact on splicing. Furthermore, this method may be implemented in clinical settings and has the 
prospects of providing many individuals the opportunity to prevent the onset of breast and/or 
ovarian cancer. However, more refinement and optimisation of this method would be required 
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 13 mL Eppendorf Centrifuge Tubes 
 RNeasy Mini Spin Columns 
 Collection Tubes (1.5 mL) 
 Collection Tubes (2 mL) 
 Buffer RLT 
 Buffer RW1 
 Buffer RPE (concentrate) 
 RNAse-Free Water 
 Sterile, RNAse-free pipette tips 
 Microcentrifuge 
 100% ethanol 
 Fresh 70% ethanol 
 18-gauge needle 




1. Pellet cells grown in suspension by centrifuging for 5 min at 300 x g in centrifuge tubes. 
Carefully remove all supernatant by aspiration.  
2. Loosen the cell pellet thoroughly by flicking the tube. Add 600 µL of Buffer RLT and vortex to 
mix.  
3. Pass the lysate at least 10 times through a 18-gauge needle fitted to an RNAse-free syringe. 
4. Add 600 µL of 70% to the homogenised lysate and mix well by pipetting. Do not centrifuge. 
5. Transfer 700 µL of the sample, including any precipitate that may have formed, to an RNeasy 
spin column placed in a 2mL collection tube. Close the lid gently, and centrifuge for 15 s at 8000 
x g. Discard the flow-through.  
6. Transfer the remaining the rest of the sample, including any precipitate that may have formed, to 
the same RNeasy spin column placed in a 2mL collection tube. Close the lid gently, and 
centrifuge for 15 s at 8000 x g. Discard the flow-through.  
7. Add 700 µL Buffer RW1 to the RNeasy spin column. Close the lid gently, and centrifuge for 15 s 
at 8000 x g to wash the spin column membrane. Discard the flow-through. 
8. Add 500 µL Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge for 15 s 
at 8000 x g to wash the spin column membrane. Discard the flow-through. 
9. Add 500 µL Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge for 2 
min at 8000 x g to wash the spin column membrane. Discard the flow-through. 




10. Place the RNeasy spin column in a new 2 mL collection tube and discard the old collection tube 
with the flow-through. Close the lid gently, and centrifuge at full 24000 x g for 1 min. 
11. Place the RNeasy spin column in a new 1.5 mL collection tube. Add 50 µL RNAse-free water 
directly to the spin column membrane. Close the lid gently, and centrifuge at full speed for 1 min 





























Appendix B:  PolyA Spin™ mRNA Isolation Kit 
Protocol Version 1.1 with Modifications 
 
Materials: 
 Kit wash buffer 
 Kit elution buffer 
 Low salt buffer 
 5 M NaCl 
 3 M NaAc 
 Glycogen solution 
 Kit microcentrifuge tubes containing oligo (dT)25 –cellulose beads in storage buffer 
 Microcentrifuge spin columns for isolation of poly(A)+ RNA 
 Microcentrifuge tubes for the deposit of isolated poly(A)+ RNA 
 95% ethanol 
 Sterile 13 x 100 mm disposable test tubes 
 Microcentrifuge 




1. Add 50 µl of 5M NaCl per 450 µl of cell lysate or total RNA solution or dissolve total RNA 
sample in 450 µl of Elution Buffer then add 50 µl of 5M NaCl. Make sure that sample is totally 
dissolved. If not, microcentrifuge for 5 minutes to pellet insoluble material. Transfer RNA solution to 
clean microcentrifuge tube.  
2. Heat at 65°C for 5 minutes and quickly cool in an ice bath for 3 minutes. 
3. Apply total RNA solution to equilibrated oligo (dT)25 -cellulose, seal cap and mix thoroughly. Let 
stand at room temperature for 5 minutes agitating by hand. 
4. Microcentrifuge for 10 seconds. Note: It is important to agitate beads during binding, washing and 
elution steps.  
5. Pipette supernatant back into original microcentrifuge tube. Repeat steps 2-4.  
6. Pipet supernatant back into original microcentrifuge tube for storage. It is recommended that no 
spin-column eluates be discarded until entire isolation procedure is completed and the results are 
evaluated. Eluates can be stored in sterile test tubes on ice.  
7. Add 400 µl of Wash Buffer to oligo (dT)25 -cellulose beads. Agitate by hand to resuspend the 
cellulose beads. Using a 1 ml micropipette with sterile pipette tip, transfer Wash Buffer and beads to 
the column reservoir of a clean microcentrifuge spin column unit (provided with kit).  




8. Let stand at room temperature for 2 minutes agitating by hand or place horizontally on rotary 
shaker. Microcentrifuge for 10 seconds. Remove column reservoir and transfer column eluent to a 
clean 13 x 100 cm test tube. 
 9. Add 400 µl of Wash Buffer to column reservoir and wash as in Step 8 three times.  
10. Using the same method wash column once with 400 µl of Low Salt Buffer. *Note: This wash step 
with 0.1 M NaCl removes residual poly(A)– RNA which is bound to the cellulose column. This step 
can be omitted during a second round purification.  
11. Remove spin-column reservoir and place in a clean microcentrifuge tube (provided with kit). 
 12. Add 200 µl of prewarmed Elution Buffer to column reservoir. Agitate by hand resuspending the 
cellulose beads. Let stand for 2 minutes agitating by hand or place on rotary shaker. Microcentrifuge 
for 10 seconds.  
13. Repeat Step 12 using fresh prewarmed Elution Buffer.  
14. Place Elution Buffer eluate on ice.  
15. Second round purification is to be done immediately. Equilibrate fresh oligo (dT)25 -cellulose 
beads and repeat isolation procedure starting at step 1.  
16. If poly(A)+ eluate is to be used at this point it can be ethanol precipitated: a) To the poly(A)+ 
eluent add 44 µl of 3 M Sodium Acetate, 20 µl of Glycogen Carrier and 1.0 ml of cold 95% ethanol. 
Allow to stand at –20°C for at least 30 minutes. At this point poly(A)+ material can be stored as an 
ethanol precipitate at –70°C until it is needed. To recover poly(A)+ material microcentrifuge for 15 
minutes at 4°C. Carefully decant supernant, then wash the pellet (often not visible) with 70% ethanol. 















Appendix C:  SuperScript™ III Reverse Transcriptase 
First-Strand cDNA Synthesis Protocol Revision Date 7 
Dec 2004 with Modifications 
 
Materials: 
 SuperScript™ III Reverse Transcriptase (200 U/ µL) 
 5X First-Strand Buffer 
 0.1 M DTT 
 Anchored Oligo(dT)20 (50 µM) 
 Total RNA 
 10 mM dNTP mix (10 mM each dATP, dGTP, dCTP and dTTP at neutral pH) 
 Sterile, distilled water 
 RNaseOUT™ Recombinant RNAse Inhibitor (40 units/µL) 




The following 20 µL reaction volume can be used for 10 pg-5 µg of total RNA or 10 pg-500 ng of 
mRNA. 
1. Add the following components to a nuclease-free microcentrifuge tube. 
1 µL of oligo(dT)20 (50µM) 
10 pg-5 µg total RNA or 10 pg-500 ng mRNA 
1 µL 10 mM dNTP Mix  
Sterile, distilled water to 13 µL 
 
2. Heat mixture to 65 °C for 5 minutes and incubate on ice for at least 1 minute. 
3. Collect the contents of the tube by brief centrifugation and add: 
4 µL 5X first-strand buffer 
1 µL 0.1 M DTT 
1 µL RNaseOUT™ Recombinant RNAse Inhibitor  
1 µL SuperScript™ III Reverse Transcriptase 
 




4. Mix by inversion and flicking. 
5. Incubate at 50 °C for 45 minutes.  
6. Inactivate the reaction by heating at 70 °C for 15 minutes.  





























Appendix D:  LongAmp® Taq PCR Kit Second-




 NEB 5X LongAmp Taq Reaction buffer 
 10 mM dNTP mix 
 5 µM GSP-T7 primer 
 LongAmp Taq 
 First strand cDNA 





1. Preheat thermocycler to 94 °C and keep all reagents on ice. 
2. In one PCR tube, place the following reagents; 
10 µL 5X LongAmp Taq Reaction Buffer 
1.5 µL 10 mM dNTPs 
4 µL 5 µM GSP-T7 primer 
2 µL LongAmp Taq 
Nuclease-free water to 50 µL 
 
3. Perform two PCR cycles using optimal annealing temperature determined via a temperature 
gradient experiment. 
94 °C for 1 min 
Annealing temperature  for 1 min 
65 °C for 30 min 
4 °C hold 
 
 




Appendix E:  HighPrep™ Magnetic Bead Clean Up 
Protocol with Modifications 
 
Materials: 
 HighPrep magnetic beads 
 Double-stranded cDNA 
 Eppendorf DNA LoBind microcentrifuge tubes 
 Magnetic rack 
 Fresh 70% ethanol 




1. Add 90 µL of resuspended HighPrep beads to 50 µL of double-stranded cDNA at room 
temperature. 
2. Incubate by inverting for 5 minutes, spin down and pellet on magnet. Discard the superntant. 
3. Keep on magnet, wash with 150 µL fresh 70% ethanol, by twisting the tube in the magnetic rack 
2x 180 °, waiting for the pellet to migrate to the other side of the tube each time.  
4. Briefly spin down, replace on magnet, pipitte off residual ethanol. 
5. Repeat steps 3-4. 
6. Resuspend pellet in 20 µL nuclease-free water, incubate at room temperature for 5 minutes by 
inversion. 
7. Pellet beads on a magnet, remove eluate of double-stranded cDNA and transfer to a fresh DNA 
















 Nuclease-free water 
 PTRI-Xef, 0.5 mg/mL (Control Template) 
 Double-stranded cDNA isolated via HighPrep magnetic beads 
 T7 enzyme mix 
 10X reaction buffer 
 ATP solution 
 CTP solution 
 GTP solution 
 UTP solution 
 
Methods: 
1.  Thaw the frozen reagents Place the RNA Polymerase Enzyme Mix on ice, it is stored in glycerol 
and will not be frozen at –20°C. Vortex the 10X Reaction Buffer and the 4 ribonucleotide 
solutions (ATP, CTP, GTP, and UTP) until they are completely in solution. Once thawed, store 
the ribonucleotides on ice, but keep the 10X Reaction Buffer at room temperature while 
assembling the reaction. All reagents should be microfuged briefly before opening to prevent loss 
and/or contamination of material that may be present around the rim of the tube.  
2. Assemble transcription reaction at room temp. The spermidine in the 10X Reaction Buffer can 
coprecipitate the template DNA if the reaction is assembled on ice. Add the 10X Reaction Buffer 
after the water and the ribonucleotides are already in the tube. The following amounts are for a 
single 20 µL reaction. Reactions may be scaled up or down if desired.   
 
2 µL ATP solution 
2 µL CTP solution 
2 µL GTP solution 
2 µL UTP solution 
2 µL 10X reaction buffer 
0.1-1 µg double-stranded cDNA or 1 µg of control template 
2 µL enzyme mix 
Nuclease-free water to 20 µL  
 




Note: For convenience, mix equal volumes of the four ribonucleotide solutions together and add 8 µL 
of the mixture to a standard 20 µL reaction instead of adding the ribonucleotides separately. 
 
3. Mix thoroughly Gently flick the tube or pipette the mixture up and down gently, and then 
microfuge tube briefly to collect the reaction mixture at the bottom of the tube.  
4. Incubate at 37°C for 4, 16 or 20 hours. The optimal incubation time for a given template will vary 


























Appendix G:  RNAClean™ XP Magnetic Bead Clean-




 Agencourt® RNACLEAN XP beads 
 Eppendorf DNA LoBind microcentrifuge tubes 
 Magnetic rack 
 Fresh 70% ethanol 
 Nuclease-free water 





1. Transfer the MEGAscript kit RNA product into an Eppendorf LoBind tube.  
2. Gently shake the Agencourt RNAClean XP bottle to resuspend any magnetic particles that may 
have settled. Add 1.8 x the volume of the RNA product.  
3. Mix the beads and sample thoroughly by inversion and flicking.  
4. Let the tube incubate at room temperature for 5 minutes before proceeding to the next step.  
5. Place the tube onto the magnetic rack for 5 minutes to separate the beads from solution. 
6. Slowly aspirate the cleared solution from the tube and discard. 
7. Dispense 1000 µL of 70% ethanol into the tube and incubate for 30 seconds at room temperature. 
Aspirate out the ethanol and discard. Repeat a total of three washes. 
8. Let the reaction tube air-dry 10 minutes on the magnetic rack with the cap open. 








Appendix H:  Oxford Nanopore Technologies Direct 
RNA Sequencing Protocol Version 




 Direct RNA sequencing kit (SQK-RNA001) 
 Magnetic rack 
 1.5 mL Eppendorf DNA LoBind tubes 
 0.2 mL thin-walled PCR tubes  
 Nuclease-free water 
 Fresh 70% ethanol  
 SuperScript III reverse transcriptase 
 10 mM dNTP mix 
 NEBNext quick ligation reaction buffer 
 Concentrated T4 DNA ligase 2M U/mL 
 Agencourt RNAClean XP beads 
 Qubit RNA HS assay kit 
 Qubit dsDNA HS assay kit  




1. Set up the MinION, flow-cell and host computer.  
2. Open the MinKNOW GUI from the desktop icon and establish a local connection.  
3. Plug the MinION into the computer. When the connection name appears under the Local tab, 
click Connect. 
4. Enter the Sample ID and FlowcellID being used, and click Submit. 
5. Click into the Sample ID box and name your sample using free text in alphanumeric format 
6. Check the number of active pores available for the experiment, reported in the message panel or 
in notifications when the check is complete. Once the check is complete, the software will return 
to the Connection page. To see the active pore report, click on notifications. If the total number of 
pores reported is lower than 800, please re-run the flow-cell check using the instructions in this 
FAQ.  
 
1. In a 0.2 ml thin-walled PCR tube, mix the reagents in the following order:  




 NEBNext Quick Ligation Reaction Buffer 3.0 µl  
RNA 9.0 µl  
RNA CS 0.5 µl  
RT Adapter (RTA) 1.0 µl  
T4 DNA Ligase 1.5 µl  
Total 15 µl  
 
Mix by pipetting and spin down. 
  
2. Incubate the reaction for 10 minutes at room temperature.  
3.  Mix the following reagents together to make the reverse transcription master mix:  
Nuclease-free water 9.0 µl  
10 mM dNTPs 2.0 µl 
 5x first-strand buffer 8.0 µl  
0.1 M DTT 4.0 µl  
Total 23.0 µl 
Add the master mix to the 0.2 ml PCR tube containing the RT adapter ligated RNA from the "RT 
Adapter ligation" step. Mix by pipetting.  
 
4. Add 2 µl of SuperScript III reverse transcriptase to the reaction and mix by pipetting. Place the 
tube in a thermal cycler and incubate at 50° C for 50 min, then 70° C for 10 min, and bring the 
sample to 4° C before proceeding to the next step.  
5. Transfer the sample to a 1.5 ml DNA LoBind Eppendorf tube. Resuspend the stock of Agencourt 
RNAClean XP beads by vortexing.  
6. Add 72 µl of resuspended RNAClean XP beads to the reverse transcription reaction and mix by 
pipetting. Incubate on a Hula mixer (rotator mixer) for 5 minutes at room temperature. 
7. Prepare 200 μl of fresh 70% ethanol in nuclease-free water. Spin down the sample and pellet on a 
magnet. Keep the tube on the magnet, and pipette off the supernatant.  
8. Keep the tube on magnet, and wash the beads with 150 µl of freshly prepared 70% ethanol 
without disturbing the pellet as described below.  
Keeping the magnetic rack on the benchtop, rotate the bead-containing tube by 180°. Wait for the 
beads to migrate towards the magnet and form a pellet.  
 Rotate the tube 180° again (back to the starting position), and wait for the beads to pellet. 
Remove the 70% ethanol using a pipette, and discard. Spin down and place the tube back on the 
magnet. Pipette off any residual 70% ethanol.  




Remove the tube from the magnetic rack and resuspend pellet in 20 µl nuclease-free water. 
Incubate for 5 minutes at room temperature. Pellet beads on magnet until the eluate is clear and 
colourless.  
Pipette 20 µl of eluate into a clean 1.5 ml Eppendorf DNA LoBind tube. 
 
9.  In a clean 1.5 ml Eppendorf DNA LoBind tube, mix the reagents in the following order:  
 
Reverse-transcribed RNA from the "Reverse Transcription" step 20.0 µl  
NEBNext Quick Ligation Reaction Buffer 8.0 µl  
RNA Adapter (RMX) 6.0 µl  
Nuclease-free water 3.0 µl  
T4 DNA Ligase 3.0 µl  
Total 40 µl Mix by pipetting.  
 
10. Incubate the reaction for 10 minutes at room temperature. Resuspend the stock of Agencourt 
RNAClean XP beads by vortexing. Add 40 µl of resuspended RNAClean XP beads to the adapter 
ligation reaction and mix by pipetting. Incubate on a Hula mixer (rotator mixer) for 5 minutes at 
room temperature. Spin down the sample and pellet on a magnet. Keep the tube on the magnet, 
and pipette off the supernatant.  
 
11. Add 150 μl of the Wash Buffer (WSB) to the beads. Close the tube lid, and resuspend the beads 
by flicking the tube. Return the tube to the magnetic rack, allow beads to pellet and pipette off the 
supernatant. Repeat. IMPORTANT Agitating the beads by flicking results in a more efficient 
removal of free adapter, compared to adding the wash buffer and immediately aspirating. Remove 
the tube from the magnetic rack and resuspend pellet in 21 µl Elution Buffer.  
12. Incubate for 10 minutes at room temperature. Pellet beads on magnet until the eluate is clear and 
colourless.  
13. Remove and retain 21 µl of eluate into a clean 1.5 ml Eppendorf DNA LoBind tube. Quantify 1 
µl of reverse-transcribed and adapted RNA using the Qubit fluorometer DNA HS assay - 
recovery aim ~200 ng. END OF STEP The reverse-transcribed and adapted RNA is now ready 
for loading into the MinION Flow-Cell.  
14. Direct RNA sequencing Priming and loading the SpotON Flow-Cell ~15 minutes IMPORTANT  
15. Thoroughly mix the contents of the RRB tube by vortexing or pipetting, and spin down briefly.  
16. Flip back the MinION lid and slide the sample port cover clockwise to that the sample port is 
visible. Priming and loading the SpotON Flow-Cell Priming and loading: The steps for priming 
and loading the SpotON Flow-Cell. Written instructions are given below. The library is loaded 
dropwise without putting the pipette tip firmly into the port. Take care to avoid introducing any 
air during pipetting. IMPORTANT Care must be taken when drawing back buffer from the flow-
cell. The array of pores must be covered by buffer at all times.  




17. Removing more than 20-30 µl risks damaging the pores in the array. After opening the priming 
port, check for small bubble under the cover. Draw back a small volume to remove any bubble (a 
few µls):  
Set a P1000 pipette to 200 µl 
Insert the tip into the priming port  
Turn the wheel until the dial shows 220-230 µl, or until you can see a small volume of buffer 
entering the pipette tip Visually check that there is continuous buffer from the priming port across 
the sensor array.  
 
18. Prepare the Flow-Cell priming mix in a clean 1.5 ml Eppendorf DNA LoBind tube. Reagent 
Volume RRB 600 µl Nuclease-free water 600 µl Total 1200 µl Load 800 µl of the priming mix 
into the flow-cell via the priming port, avoiding the introduction of air bubbles. Wait for 5 
minutes. IMPORTANT Thoroughly mix the contents of the RRB tube by vortexing or pipetting, 
and spin down briefly. Take 20 µl of the prepared RNA library and mix it with 17.5 µl of 
nuclease-free water.  
19. In a new tube, prepare the library for loading as follows: Reagent Volume RRB 37.5 µl RNA 
library in nuclease-free water 37.5 µl Total 75 µl Complete the flow-cell priming:  
Gently lift the SpotON sample port cover to make the SpotON sample port accessible.  
Load 200 µl of the priming mix into the flow-cell via the priming port (not the SpotON sample 
port), avoiding the introduction of air bubbles. Mix the prepared library gently by pipetting up 
and down just prior to loading.  
20. Add 75 μl of sample to the Flow-Cell via the SpotON sample port in a dropwise fashion. Ensure 
each drop flows into the port before adding the next. Gently replace the SpotON sample port 
cover, making sure the bung enters the SpotON port, close the priming port and replace the 











Appendix I:  RNA-seq data from Makenzie Cancer 
Research Group (MCRG) with RNA from a Control 
Lymphoblastoid Cell Line (08.111.0064) 
 
Chromosome Start Stop Splicing 
event 





12            
6,643,736  
           
6,643,975  
FL 1-2 GAPDH 90053 38445 
12            
6,643,736  
           
6,645,659  
Delta 2 GAPDH 33 16 
12            
6,643,828  
           
6,643,975  
FL 1b-2 GAPDH 327 120 
12            
6,644,028  
           
6,645,659  
FL 2-3 GAPDH 174336 86509 
12            
6,644,028  
           
6,646,085  
Delta 3_4 GAPDH 9 4 
12            
6,645,721  




GAPDH 631 240 
12            
6,645,760  
           
6,645,849  
FL 3-4 GAPDH 170204 94922 
12            
6,645,957  
           
6,646,085  
FL 4-5 GAPDH 156870 111090 
12            
6,646,177  
           
6,646,266  
FL 5-6 GAPDH 119868 98803 
12            
6,646,177  
           
6,646,474  
Delta 6 GAPDH 2 0 
12            
6,646,356  
           
6,647,266  
delta 6q delta 
7_8 
GAPDH 1474 1545 
12            
6,646,383  
           
6,646,474  
FL 6-7 GAPDH 179721 209243 
12            
6,646,383  
           
6,646,503  
exon 6 - mid 
exon 7 
GAPDH 49 56 
12            
6,646,383  
           
6,646,749  
Delta 7 GAPDH 8 0 
12            
6,646,383  
           
6,647,266  
Delta 7_8 GAPDH 1 5 
12            
6,646,518  
           
6,646,881  
Mid exon 7- 
mid exon 8 
GAPDH 8693 12273 
12            
6,646,557  
           
6,646,749  
FL 7-8 GAPDH 203336 274910 
12            
6,646,557  
           
6,647,266  
Delta 8 GAPDH 6 36 
12            
6,646,873  




GAPDH 7095 10236 
12            
6,647,163  
           
6,647,266  
FL 8-9 GAPDH 152837 517299 




17          
41,197,820  
         
41,199,659  
FL 23-24 BRCA1 376 64 
17          
41,197,820  
         
41,201,137  
Delta 23 BRCA1 2 1 
17          
41,199,721  
         
41,201,137  
FL 22-23 BRCA1 345 55 
17          
41,199,721  
         
41,203,079  
Delta 22 BRCA1 5 1 
17          
41,201,212  
         
41,203,079  
FL 21-22 BRCA1 494 67 
17          
41,201,212  
         
41,209,068  
Delta 21 BRCA1 5 0 
17          
41,203,135  
         
41,209,068  
FL 20-21 BRCA1 504 63 
17          
41,209,153  
         
41,215,349  
FL 19-20 BRCA1 490 41 
17          
41,215,391  
         
41,215,890  
FL 18-19 BRCA1 509 40 
17          
41,215,969  
         
41,219,624  
FL 17-18 BRCA1 486 35 
17          
41,215,969  
         
41,222,944  
Delta 17 BRCA1 4 0 
17          
41,219,713  
         
41,222,944  
FL 16-17 BRCA1 466 46 
17          
41,223,256  
         
41,226,347  
FL 15-16 BRCA1 579 60 
17          
41,223,256  
         
41,228,504  
Delta 15 BRCA1 5 0 
17          
41,226,539  
         
41,228,504  
FL 14-15 BRCA1 522 57 
17          
41,226,539  
         
41,234,420  
Delta 14 BRCA1 1 2 
17          
41,228,632  
         
41,234,420  
FL 13-14 BRCA1 338 29 
17          
41,228,632  
         
41,242,960  
Delta 13 BRCA1 1 0 
17          
41,234,593  
         
41,242,960  
FL 12-13 BRCA1 446 28 
17          
41,243,050  
         
41,243,451  
FL 11-12 BRCA1 427 24 
17          
41,243,050  
         
41,247,862  
Delta 11 BRCA1 4 0 
17          
41,243,050  
         
41,251,791  
Delta 9_11 BRCA1 5 2 
17          
41,246,878  
         
41,247,862  
FL 10-11 BRCA1 287 6 
17          
41,246,878  
         
41,249,260  
Delta 10 BRCA1 2 0 
17          
41,246,878  
         
41,251,791  
Delta 9_10 BRCA1 158 8 
17          
41,246,878  
         
41,256,138  
Delta 8_20 BRCA1 1 0 
17          
41,247,940  
         
41,249,260  
FL 9-10 BRCA1 222 3 




17          
41,247,940  
         
41,251,791  
Delta 9 BRCA1 57 0 
17          
41,249,307  
         
41,251,791  
FL 8-9 BRCA1 226 3 
17          
41,251,898  
         
41,256,138  
FL 7-8 BRCA1 405 18 
17          
41,256,279  
         
41,256,884  
FL 6-7 BRCA1 452 13 
17          
41,256,974  
         
41,258,472  
FL 5-6 BRCA1 382 10 
17          
41,256,974  
         
41,267,742  
Delta 5 BRCA1 8 0 
17          
41,256,974  
         
41,276,033  
Delta 3_5 BRCA1 1 0 
17          
41,258,551  
         
41,267,742  
FL 3-5 BRCA1 404 11 
17          
41,258,551  
         
41,276,033  
Delta 3 BRCA1 8 0 
17          
41,267,797  
         
41,276,033  
FL 2-3 BRCA1 344 11 
17          
41,267,797  
         
41,277,287  
Delta 2 BRCA1 1 0 
17          
41,276,133  
         
41,277,287  
FL 1-2 BRCA1 86 3 
17          
56,770,150  
         
56,772,291  
FL 1-2 RAD51C 1147 336 
17          
56,770,150  
         
56,774,053  
Delta 2 RAD51C 1 0 
17          
56,772,551  
         
56,774,053  
FL 2-3 RAD51C 1229 189 
17          
56,772,551  
         
56,780,556  
Delta 3 RAD51C 65 0 
17          
56,772,551  
         
56,811,478  
Delta 3_8 RAD51C 1 0 
17          
56,774,221  
         
56,780,556  
FL 3-4 RAD51C 904 152 
17          
56,774,221  
         
56,787,219  
Delta 4 RAD51C 16 2 
17          
56,780,691  
         
56,787,219  
FL 4-5 RAD51C 1004 208 
17          
56,787,352  
         
56,798,106  
FL 5-6 RAD51C 1318 383 
17          
56,787,352  
         
56,801,400  
Delta 6 RAD51C 7 1 
17          
56,787,352  
         
56,809,844  
Delta 6_7 RAD51C 1 0 
17          
56,787,352  
         
56,811,478  
Delta 6_8 RAD51C 3 3 
17          
56,798,174  
         
56,801,400  
FL 6-7 RAD51C 1235 328 
17          
56,798,174  
         
56,809,844  
Delta 7 RAD51C 50 28 
17          
56,798,174  
         
56,811,478  
Delta 7_8 RAD51C 5 19 




17          
56,801,462  
         
56,809,844  
FL 7-8 RAD51C 1076 362 
17          
56,801,462  
         
56,811,478  
Delta 8 RAD51C 4 0 
22          
29,083,975  
         
29,085,122  
FL 14-15 CHEK2 461 756 
22          
29,085,204  
         
29,090,019  
FL 13-14 CHEK2 411 554 
22          
29,090,106  
         
29,091,114  
FL 12-13 CHEK2 547 666 
22          
29,091,231  
         
29,091,697  
FL 11-12 CHEK2 394 455 
22          
29,091,231  
         
29,095,825  
Delta 10_11 CHEK2 7 0 
22          
29,091,862  
         
29,092,888  
FL 10-11 CHEK2 449 291 
22          
29,091,862  
         
29,095,825  
Delta 10 CHEK2 21 17 
22          
29,092,976  
         
29,095,825  
FL 9-10 CHEK2 412 240 
22          
29,095,926  
         
29,099,492  
FL 8-9 CHEK2 287 177 
22          
29,095,926  
         
29,105,993  
Delta 8 CHEK2 109 34 
22          
29,099,555  
         
29,105,993  
FL 7-8 CHEK2 231 148 
22          
29,106,048  
         
29,107,896  
FL 6-7 CHEK2 404 245 
22          
29,108,006  
         
29,115,382  
FL 5-6 CHEK2 355 166 
22          
29,108,006  
         
29,120,964  
Delta 5 CHEK2 28 15 
22          
29,108,006  
         
29,121,230  
Delta 4_5 CHEK2 12 0 
22          
29,115,474  
         
29,120,964  
FL 4-5 CHEK2 232 139 
22          
29,121,113  
         
29,121,230  
FL 3-4 CHEK2 418 188 
22          
29,121,356  
         
29,130,390  
FL 2-3 CHEK2 420 128 
 
 
 
